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3ABSTRACT
BACKGROUND AND OBJECTIVES
Rational use of antimicrobials is paramount due to increasing bacterial resistance 
and a lack of novel antimicrobials. Investigating the clinical use and consumption 
of antimicrobials aids in the prudent use of these drugs in a tertiary paediatric 
hospital. The purpose of this study was to obtain detailed information on the use 
of antimicrobials in a tertiary Children’s Hospital, Helsinki University Hospital 
(HUCH), in order to support prudent, safe and efficient use of antimicrobials. The 
consumption of antimicrobials and the quality and appropriateness of antimicrobial 
therapy (AMT) was investigated at the hospital level as well as in individual patient 
cases. The objectives were the following: 1) To evaluate the appropriateness of AMT 
in children with blood culture positive infections (Study I), 2) To investigate the 
consumption of antimicrobials in the hospital in Defined Daily Doses (Study II), 3) 
To record the prevalence of off-label (OL) use of antimicrobials in neonates (Study 
III) and last, 4) To analyse the occurrence of antimicrobial medication errors in 
children (Study IV).
MATERIALS AND METHODS
The Children’s Hospital, University of Helsinki, is a tertiary hospital in Finland. 
Its departments include general paediatrics, paediatric surgery, oncology, 
transplantation and both paediatric and neonatal intensive care units (PICU, NICU). 
The hospital has approximately 130 beds. The average annual number of patient 
days is approximately 30,000 days. 
Two of the studies involved individual patients. In Study I, data on 149 children 
(0–17 years) with blood culture positive hospital infections between 2005 and 
2012 were collected. An expert panel evaluated the appropriateness of the targeted 
AMT. In Study III, the prevalence of OL use of antimicrobials was investigated 
in three different paediatric cohorts. The largest cohort consisted of premature 
NICU patients (450–2000g) with blood culture positive infections and antimicrobial 
therapy given between 2005 and 2014 (N=282). Overall, different types of methods 
were used regarding quantitative and qualitative analysis and retrospective reviews 
of electronic patient records and data. 
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Studies II and IV were registry studies. In Study II, the consumption of antimicrobials 
in Defined Daily Doses (DDDs according to the Anatomical Therapeutic Chemical 
(ATC)/DDD index) was investigated retrospectively between 2003 and 2013. In 
Study IV, the types of antimicrobial errors were analysed. The errors were reported 
by healthcare professionals using a voluntary web-based error reporting system, 
HaiPro. The data were obtained between June 2009 and December 2014 from four 
different medical wards. The majority of the studies were conducted retrospectively. 
Analysis of the studies was both quantitative and qualitative.
RESULTS
The AMT was inappropriate in 17% (26/149) of patients with blood culture positive 
infections (Study I). Three of these patients received antimicrobials that were totally 
ineffective according to in vitro data. Suboptimal or overly broad-spectrum AMT 
was administered to 13/26 (50%) patients. Increased bacterial resistance was 
likewise discovered. The use of certain anti-Pseudomonas antimicrobials, such 
as carbapenems, piperacillin tazobactam and ceftazidime, has increased notably 
during 11 years (Study II). During 2003 and 2013, the use of many beta-lactam 
antimicrobials increased. The most notable change was in the use of carbapenems, 
which increased by 110% during the study period. In the Children’s Hospital, OL 
use of antimicrobials is relatively common. In NICU, 35% (7/20) of consumed 
antimicrobials were off-label in neonates between 2009 and 2014 (Study III). A total 
of 18% (51/282) of premature neonates with blood culture positive infection received 
at least one OL antimicrobial. An increase in birth weight was found to statistically 
significantly decrease the probability of OL usage (odds ratio=0.85 for 100g increase 
in birth weight, p-value < 0.001). Medication errors likewise compromised patient 
care and safety. In Study IV, there were 157 antimicrobial errors reported in 149 
patients from four wards (GEN, NICU, HEM-ONC and INF). The majority of the 
reported errors (125/149, 84%) reached the patient. No fatal errors occurred. Two 
errors were reported as clinically significant (2/149, 1%). Most of the errors occurred 
with drugs with high consumption, such as cefuroxime (15/157, 10%) and penicillin 
G (15/157, 10%). Omission errors were the typical error with antimicrobials (37/149, 
25%). The results from Studies I–IV further confirm multiple problems regarding 
the issues of declining paediatric medication safety and increasing antimicrobial 
resistance.
5CONCLUSIONS 
These studies gave a useful overall picture regarding AMT and the use of 
antimicrobials at the Children’s Hospital. More attention should be paid to 
appropriate AMT, and training of prescribers should be provided. The increased 
use of carbapenems highlights constantly increasing microbial resistance. With 
premature neonates, the smaller the birth weight was, the higher the risk of OL 
antimicrobial use. Fortunately, antimicrobial medication errors were infrequently 
harmful to patients. This thesis provides a window into issues that undermine the 
quality of care regarding hospital infections in paediatrics and aids the launch of 
an antimicrobial stewardship program (ASP) in the Children’s Hospital.
Keywords: antibacterial, antibiotic, antifungal, antimicrobial, antimicrobial 
stewardship program, antiviral, appropriate use, bacteria, blood culture positive 
infection, bloodstream infections (BSI), children, children’s hospital, defined daily 
doses (DDDs), infectious diseases, label use, medication error, medication safety, 
neonatal intensive care unit (NICU), neonate, off-label use, pathogen, paediatric, 
paediatrics intensive care unit (PICU), paediatric, sepsis
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TAUSTA JA TAVOITTEET
Mikrobilääkkeiden rationaalinen käyttö on tärkeää. Mikrobilääkeresistenssi 
kasvaa jatkuvasti ja uusia mikrobilääkkeitä ei ole riittävästi. Mikrobilääkkeiden 
asianmukaista käyttöä tertiäärisessä lastensairaalassa tukee kliinisen käytön ja 
kulutuksen tutkiminen. 
Tämän väitöstyön tavoite oli saada yksityiskohtaista tietoa mikrobilääkkeiden 
käytöstä tertiäärisessä lastensairaalassa (HUS), jotta voidaan tukea rationaalista, 
turvallista ja tehokasta mikrobilääkkeiden käyttöä. Mikrobilääkkeiden 
kulutus ja mikrobilääkehoidon laatu ja oikeellisuus tutkittiin sairaalatasolla 
sekä potilastapauksilla. Väitöstyön tavoitteet olivat seuraavat: 1) Arvioida 
mikrobilääkehoidon oikeellisuus lapsilla, jotka saivat mikrobilääkehoitoa 
veriviljelypositiivisiin infektioihin (Osatutkimus 1.), 2) Tutkia mikrobilääkkeiden 
kulutus sairaalassa käyttäen DDD-lukuja (Defined Daily Doses) (Osatutkimus 2.), 
3) Tutkia ei-rekisteröityjen mikrobilääkkeiden käytön prevalenssia vastasyntyneillä 
(Osatutkimus 3.), 4) Analysoida sattuneet mikrobilääkehoitoon liittyneet 
lääkityspoikkeamat lapsilla (Osatutkimus 4.). 
MATERIAALIT JA METODIT
Lastenklinikka, Helsingin yliopistollinen sairaala, on tertiäärinen sairaala Suomessa. 
Sen osastoihin kuuluvat lastentaudit, kirurgiset osastot, syöpätaudit, elinsiirto-osasto 
ja vastasyntyneiden ja lasten teho-osastot. Sairaalassa on noin 130 vuodepaikkaa. 
Vuosittaisia hoitopäiviä tulee keskimäärin 30 000.
Kahdessa osatyössä oli mukana potilaita. Osatyössä 1., 149 veriviljelypositiivista 
infektiota sairastavan potilaan aineisto (iältään 0–17 vuotta) kerättiin vuosilta 
2005–2012. Erityisasiantuntijat arvioivat kohdennetun mikrobilääkehoidon 
oikeellisuuden. Osatyössä 3. ei-rekisteröityjen mikrobilääkkeiden käytön prevalenssi 
tutkittiin kolmella erilaisella pediatrisella kohortilla. Suurin kohortti koostui 
ennenaikaisesti syntyneistä vastasyntyneiden teho-osaston potilaista (450–2000g), 
joilla oli veriviljelypositiivinen infektio ja infektioon annettu mikrobilääkehoito 
vuosina 2005–2014 (N=282). Kaiken kaikkiaan erilaisia metodeja käytettiin 
kvantitatiivisessa ja kvalitatiivisessa retrospektiivisissä potilastietojen analyysissa.
7Osatyöt 2. ja 4. olivat rekisteritutkimuksia. Osatyössä 2. mikrobilääkkeiden 
kulutus vuosina 2003–2013 tutkittiin käyttäen DDD-lukuja. Osatyössä 4. 
analysoitiin raportoitujen mikrobilääkityspoikkeamien tyyppiä. Poikkeamat 
raportoitiin vapaaehtoisesti elektronisen HaiPro työkalun avulla terveydenhuollon 
ammattilaisten toimesta. Aineisto kerättiin vuosilta kesäkuu 2009 – joulukuu 2014. 
Suurin osa osatöistä tehtiin retrospektiivisesti. Analyysi oli sekä kvantitatiivista että 
kvalitatiivista. 
TULOKSET
Mikrobilääkehoito oli epäasianmukaista 17% (26/149) potilaista, joilla 
oli veriviljelypositiivinen infektio (Osatyö 1.). Näistä potilaista kolme sai 
mikrobilääkehoitoa, joka oli täysin tehotonta taudinaiheuttajia vastaan in vitro 
aineiston mukaan. Suboptimaalista tai liian laajakirjoista mikrobilääkehoitoa 
annettiin 13/26 (50%) potilaista. Myös mikrobilääkehoitoon liittyvä kasvanut 
resistenssi havaittiin, tiettyjen anti-Pseudomonas mikrobilääkkeiden, kuten 
karbapeneemien, piperasilliini-tatsobaktaamin ja keftatsidiimin, käyttö kasvoi 
huomattavasti 11 vuoden aikana. (Osatyö 2.). Vuosina 2003–2013 resistenssi kasvoi 
useita beeta-laktaamiantibiootteja kohtaan. Merkittävin muutos oli karbapeneemien 
käytössä, joka kasvoi tutkimusaikavälillä 110%. Lastenklinikalla ei-rekisteröityjen 
lääkkeiden käyttö on suhteellisen yleistä. Vastasyntyneiden teho-osastolla 35% 
(7/20) käytetyistä mikrobilääkkeistä on ei-rekisteröityjä vastasyntyneillä vuosina 
2009–2014 (Osatyö 3.). Kaiken kaikkiaan 18% (51/282) keskosista, joilla oli 
veriviljelypositiivinen infektio, sai ei-rekisteröityä mikrobilääkettä. Kasvun 
syntymäpainossa havaittiin olevan tilastollisesti merkittävästi yhteydessä ei-
rekisteröityjen mikrobilääkkeiden käyttöön (odds ratio =0.85, 100g kasvua 
syntymäpainossa, p-arvo < 0.001). Lääkityspoikkeamat uhkasivat myös 
lastenlääkitysturvallisuutta. Osatyössä 4. raportoitiin 157 mikrobilääkityspoikkeamaa 
149 potilaalla neljältä osastolta (GEN, NICU, HEM-ONC ja INF). Suurin osa 
raportoiduista poikkeamista (125/149, 84%) tapahtui potilaille. Kuolemaan johtavia 
poikkeamia ei sattunut. Kaksi raportoitua poikkeamaa oli kliinisesti merkittäviä 
(2/149, 1%). Suurin osa poikkeamista sattui mikrobilääkkeillä, joita käytettiin usein, 
kuten kefuroksiini (15/157, 10%) ja G penisilliini (15/157, 10%). Lääkkeen annon 
unohtaminen oli tyypillinen poikkeama mikrobilääkkeillä (37/149, 25%). Osatöiden 
1.–4. tulokset varmistavat entisestään useita lastenlääkitysturvallisuutta heikentäviä 
tekijöitä sekä kasvaneen mikrobilääkeresistenssin sairaalassa. 
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JOHTOPÄÄTÖKSET
Nämä tutkimukset antoivat hyödyllisen yleiskuvan mikrobilääkehoidosta ja 
mikrobilääkkeiden käytöstä Lastenklinikalla. Asianmukaiseen mikrobilääkehoitoon 
ja lääkkeenmäärääjien koulutukseen tulisi kiinnittää enemmän huomiota. 
Karbapeneemien kasvanut käyttö korostaa kasvanutta mikrobilääkeresistenssiä. 
Mitä pienempi syntymäpaino keskosella oli, sen todennäköisemmin keskonen 
sai ei-rekisteröityjä mikrobilääkkeitä. Mikrobilääkityspoikkeamat eivät onneksi 
olleet usein haitallisia potilaille. Tämä väitöstyö tarjoaa näkökulman tekijöihin, 
jotka heikentävät sairaalainfektioiden hoidon laatua lastensairaalassa, sekä edistää 
mikrobilääkkeiden käytön ohjausjärjestelmän rakentamista Lastenklinikalle.
Hakusanat: antibiootti, asianmukainen käyttö, bakteeri(t), bakteerilääke, 
bakteremia, ei-rekisteröityjen lääkkeiden käyttö, infektiotaudit, lapset, lasten 
teho-osasto, lastensairaala, lääkekulutustiedot (DDD-luvut), lääkityspoikkeama, 
lääkitysturvallisuus, mikrobilääke, patogeeni, pediatrinen, mikrobilääkkeiden 
käytön ohjausjärjestelmä, rekisteröity käyttö, sepsis, sienilääke, vastasyntyneiden 
teho-osasto, vastasyntynyt, veriviljelypositiivinen infektio, viruslääke
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DEFINITIONS OF KEY CONCEPTS
Administration error, in Study IV administration errors include omission 
(forgetting to administer the drug), wrong dose/dosing interval, wrong drug given 
and otherwise inappropriate administration. This is due to the categorization in 
the HaiPro system.
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GARPEC (Global Antimicrobial Resistance, Prescribing, and Efficacy among 
Neonates and Children). GARPEC project is a global surveillance network focused 
on collection of data on neonatal and paediatric antimicrobial prescribing and 
resistance.
Empirical antimicrobial therapy, antimicrobial given when infection is 
suspected and the causative pathogen is not yet known.
HaiPro, web-based tool for anonymous and voluntary reporting for healthcare 
professionals in Finland. 
Healthcare-associated infection (HCAI), an infection that occurs in a patient 
during the process of care in a hospital or other healthcare facility that was not 
present or incubating at the time of admission. 
Hospital-acquired bacteremia, in Study I, this was determined according to 
the classic CDC criteria, where laboratory-confirmed bloodstream infection is LCBI. 
LCBI is equivalent to the determination of healthcare-associated BSI in Study I. 
Label drug, label use of a drug
Medication error, a medication error is an unintended failure in the drug 
treatment process that leads to, or has the potential to lead to, harm to the patient.
Neonate, child less than 30 days old
Off-label drug, in Study III off-label (OL) drug use was determined as following: 
Off-label drug use occurs when a drug is administered for indication(s) not given 
in drug’s summary of product characteristics (SPC).
OL, off-label use of a drug
Omission error, forgetting to administer a drug on time 
Premature neonate, in Study III premature neonates were neonates weighting 
400–2000g 
Sepsis, life-threatening organ dysfunction caused by a dysregulated host response 
to infection
Targeted antimicrobial therapy, antimicrobial therapy given after receiving 
final culture results on causative pathogens
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1. Introduction
1. INTRODUCTION
As users of pharmaceuticals, children are a vulnerable group, and more effort should 
be placed on research investigating appropriate use of drugs in paediatrics. There is 
a large gap in knowledge on how to safely and effectively use many different drugs in 
children. However, during the past decade, efforts have been conducted to increase 
the knowledge of drug use in children. One such effort is the Paediatric Regulation 
that came into force in 2007 [1]. Despite these recent positive developments in 
paediatric research, more knowledge is still required, particularly regarding data 
on dosing and pharmacokinetics [2]. Numerous issues, such as off-label use and 
extrapolating drug dosages from adult formulations to children, weaken paediatric 
medication safety. Dosages need to be adapted to paediatric patients based on age 
groups because the ADME processes (absorption, distribution, metabolism and 
excretion) vary according to age and the developmental processes of children.
Off-label (OL) use of drugs in children is common [3, 4]. It is estimated that 
out of all pharmaceuticals used in children, approximately 50% are being used OL. 
The use of OL drugs in children’s hospitals varies between 12% and 71% [4, 5–12]. 
In certain groups of patients, such as neonates, it can be as high as between 48% 
and 89% [4, 5, 6, 10, 11]. In European NICUs (Neonatal Intensive Care Units), 
the prevalence of OL use was between 28% and 100% [13–17]. Furthermore, in 
premature neonates the prevalence of OL use is known to vary between 91% and 
100% [13, 14, 16]. 
Despite common use of antimicrobials in hospitalized children, many antibiotics 
do not have a market authorization in paediatrics, especially in neonates (preterm 
and full-term) [2]. The OL use of antibiotics is relatively common in hospitalized 
children, although many antimicrobials lack data on dosing, pharmacokinetics, 
safety, efficacy and clinical use in paediatrics. This leads to a number of issues that 
threaten paediatric medication safety: lack of available dosage forms, individual 
doses must be calculated based on age, weight and/or body surface area, disease(s) 
and clinical condition. Adverse effects follow more often if drugs are used OL, and 
there is lack of research standards since no prescribing standard exists [18].
The use of drugs may also predispose patients to medication errors. The frequency 
of medication errors in children is more common than in adults [19]. In addition, 
when an error occurs, children are more prone to clinically significant harm [20]. 
Children are more prone to errors for numerous reasons [21], one being the relatively 
common use of OL drugs in children despite the fact that data on optimal doses, 
etc., are not available. It is estimated that medication errors are three times more 
likely to occur in children versus adults [22–33]. Medication errors occurring with 
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antimicrobial therapy (AMT) in children is an area lacking in research, with only a 
few studies focused on this area [28, 30]. Investigating the occurrence of medication 
errors is imperative in order to learn how to prevent these errors and to promote 
medication safety. 
The judicious use of antimicrobials is of similarly high importance. Resistance 
towards antimicrobials is growing constantly [34]. In addition, the development 
of novel antimicrobials has not been very successful lately. It also requires time 
and major funding. Battling against antimicrobial resistance in hospital settings 
can be done in multiple ways, such as implementing antimicrobial stewardship 
programs (ASPs), monitoring the consumption of antimicrobials and focusing on 
the individual antimicrobial courses given to patients [35]. These measures should 
reduce the use of overly broad-spectrum antimicrobials and help reserve these 
precious drugs for circumstances where they are a necessity. The AMT should be 
carefully monitored during an infection. Starting an empirical AMT often involves 
the use of broad-spectrum antimicrobials when the causative pathogen(s) are 
unknown. However, after the microbiological results are available, especially results 
from the blood culture, the identification of the pathogen(s) allows us to re-evaluate 
the AMT. There are surprisingly few studies that have investigated the effect of blood 
culture results in the subsequent AMT in hospital infections in paediatrics. This 
would be important research since the use of overly broad-spectrum antimicrobials 
increases overall resistance and exposes patients to resistant microbes and adverse 
effects such as C.Difficile infections [36–38]. 
This dissertation investigates the use of antimicrobials in the Children’s Hospital, 
Helsinki University Central Hospital. The aim of the dissertation was to improve 
the quality of AMT in the Children’s Hospital as well as to produce data on the 
use of antimicrobials in children. The AMT given to children was investigated 
using different approaches that provided different data, which are presented in 
the following studies (I–IV). The appropriateness, quality and safety of AMT were 
investigated in individual patient cases as well as at the hospital level. The analysis 
was both qualitative and quantitative. 
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2. REVIEW OF THE LITERATURE
The literature reviews and literature searches were done regarding use of 
antimicrobials in children´s hospitals. A literature review was conducted on the 
evaluation of appropriateness of antimicrobial therapy (AMT), and a systematic 
literature review was conducted on medication errors in hospitalized children. 
Off-label use of antimicrobials was investigated by comparing local and global 
categorizations and patterns of use. 
2.1. HEALTHCARE-ASSOCIATED INFECTIONS IN CHILDREN
2.1.1. GENERAL PRINCIPLES OF HEALTHCARE-ASSOCIATED INFECTIONS
A healthcare-associated infection (HCAI) is an infection that occurs in a patient 
during the process of care in a hospital or other healthcare facility, which was not 
present or incubating at the time of admission [39]. When referring to HCAIs, the 
terms “hospital infection” and “nosocomial infection” are also used. HCAIs can 
start from an infected organ, such as bladder or lungs, and progress to bloodstream 
infection where the causative pathogen(s) are in the blood. Pathogens can also 
access the bloodstream directly from cannulas or via other invasive routes, for 
example, during surgery. Incubation time varies according to causative pathogen(s), 
and infections emerging when the patient is hospitalized should be considered as 
HCAIs. When the causative agent is bacteria, HCAI usually becomes detectable in 
48 hours [40]. 
The burden resulting from HCAIs is enormous. Worldwide, HCAIs affect the lives 
of hundreds of million patients annually [39]. HCAIs are associated with prolonged 
hospital stays, disability, antimicrobial resistance, rising costs for healthcare systems 
and an increased burden on patients and their families. In addition, significant 
mortality and morbidity can be caused by HCAIs, and this is especially true in 
neonates with central line -associated bloodstream infections and ventilator-
associated pneumonia [41–44]. 
2.1.2. HEALTHCARE-ASSOCIATED INFECTIONS IN PAEDIATRICS
The most common bacterial HCAIs in children are surgical site infections (SSIs), 
lower respiratory tract infections and bloodstream infections (BSIs) [45]. The 
prevalence of HCAIs in European paediatric hospitals varies between 1.2% and 
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10.4% [46]. There is also variation between different medical wards regarding the 
prevalence of HCAIs. The highest rates have been recorded in paediatric intensive 
care units and neonatal intensive care units (PICUs and NICUs) [46, 47]. In the 
Children’s Hospital, healthcare-associated infections have most often been reported 
in patients on haematology and neonatology wards [48]. The prevalence of HCAIs 
in children has been published to be the highest during the first year of life [46]. 
Overall, the prevalence of HCAIs has been reported to be between 9% and 21% in 
critically ill children [41, 49–51]. 
The causative pathogens in paediatric HCAIs are mostly bacteria. According 
to a study from the European Centre for Disease Prevention and Control (ECDC) 
conducted in European children’s hospitals, 88% of causative pathogens in 
HCAIs were bacteria, 7% fungi and 5% viruses [46]. The most common bacteria 
identified were coagulase-negative staphylococci (CONS), Enterobacteriaceae 
and Staphylococcus aureus. Respiratory infections caused by viruses are also very 
frequents pathogens. Rotavirus and norovirus are common causative pathogens in 
gastroenteritis. However, infections caused by fungi, such as Candida, are relatively 
rare.
2.1.3. BLOODSTREAM INFECTIONS IN PAEDIATRICS
Bloodstream infections (BSIs) are infections where the pathogens, usually bacteria, 
can be identified from a blood culture sample. Blood culture positive infections are 
infections where the pathogen has been identified from the blood culture sample. 
Very frequently the blood culture remains negative. This does not, however, mean 
that the infections are not caused by bacteria. A negative culture may reflect low 
numbers of bacteria in the blood. Such infections are called culture negative 
infections. They may also be referred to as clinical infections with negative blood 
cultures. BSIs are among the most common HCAIs in paediatrics [52–54]. In 
European paediatric hospitals, BSIs were the most common HCAIs representing 
41.0–48.1% of all HCAIs recorded [46]. The majority of the BSIs were reported in 
infants less than 12 months of age. In the Children’s Hospital, the prevalence of 
blood culture positive infections has been reported to be 1.6 infections/1000 days 
of care (Figure 1). 
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Figure 1. Number of healthcare-associated blood culture positive infections/year in the Children´s Hospital, 
Helsinki University Hospital from 2005–2012.
The most common causative pathogens of blood culture positive infections were 
Gram positive cocci in the Children’s Hospital (Figure 2). Bacteremias can progress 
to sepsis, which is a life-threatening organ dysfunction caused by a dysregulated 
host response to infection [55]. Furthermore, in septic shock, circulatory, cellular 
and metabolic abnormalities are associated with a greater risk of mortality than 
with sepsis alone. Recently, a new score to describe sepsis was developed [56]. The 
Sepsis-related Organ Failure Assessment (SOFA) score is more accurate than the 
numerous previous definitions, and it can be used both to monitor the patient and 
to calculate the patient’s prognosis. 
When a BSI is suspected, rapid initiation of adequate empirical antimicrobial 
therapy (AMT) is of paramount importance. The selection of appropriate therapy 
is, however, challenging since it should cover the most likely causative pathogens. 
It has been shown by Welsh et al. [57] that selection of suboptimal therapy clearly 
affects the prognosis of the patient. On the other hand, the use of an excessively 
broad-spectrum antimicrobial therapy can expose the patient to opportunistic 
infections caused by multiresistant organisms, fungi or Clostridium difficile colitis. 
In addition, multiple co-morbidities in the patient as well as numerous side effects 
of the antibiotics further complicate the choice of appropriate therapies. 
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Figure 2. 944 episodes of blood culture positive infections in 793 children in the Children´s Hospital, 
Helsinki University Hospital from 2005–2012. 
2.2.  ANTIMICROBIAL THERAPY FOR HEALTHCARE-
ASSOCIATED INFECTIONS 
2.2.1. EMPIRICAL AND TARGETED ANTIMICROBIAL THERAPY
When an infection is suspected in a hospitalized patient, initiating AMT as soon 
as possible is of crucial importance. AMT is empirical until the pathogens are 
identified from samples such as urine, sputum or blood culture. Hence, empirical 
AMT is aimed at the most probable causative pathogens and is generally of broader 
spectrum compared to targeted AMT. When prescribing targeted AMT, the causative 
pathogens are known and AMT can be more focused (de-escalated) towards the 
identified pathogens. 
2.2.2.  APPROPRIATENESS AND INAPPROPRIATENESS OF ANTIMICROBIAL 
THERAPY FOR HEALTHCARE-ASSOCIATED INFECTIONS
Inappropriate use of AMT occurs in several ways, such as prescribing antibiotics 
with no or suboptimal efficacy against the pathogens. In addition, failure of de-
escalation of the therapy should also be considered inappropriate. Investigating 
the quality of AMT is a complex topic requiring multiple factors to be considered. 
Hence, a MedLine-based literature review was conducted in January 2012 in order 
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to discover how appropriate or inappropriate AMT for HCAIs had been used in 
different hospital settings (Table 1.). Studies conducted in adults were included 
since no studies focusing on paediatrics were found. 
Table 1. Inclusion criteria for the literature review appropriate vs. inappropriate antimicrobial therapy (AMT) 
for HCAIs (healthcare-associated infections).
• study conducted from the year 2000 onwards
• language English
• study conducted in hospital environment
• both paediatric and adult studies were included
• study on AMT in hospitalized patients 
• search terms: bloodstream infection, blood culture positive infection, sepsis, 
hospital, antimicrobial therapy, antibiotic, inappropriate, appropriate, 
paediatric
The search yielded 392 articles, of which 10 met the inclusion criteria (Tables 1. and 
2.). The majority of the studies focused on adults. These studies applied different 
approaches and used a large variety of definitions of appropriate AMT (Table 3.). 
Some studies evaluated only the appropriateness of empiric therapy of serious 
infections [58–60], while others looked at targeted therapy as well [60–65]. Some 
of the studies focused specifically on verified BSI [58–60, 65] and others on the 
quality of the AMT in general [62,73]. 
Three studies focused on appropriateness of empirical AMT. These three studies 
had similar, relatively simple definitions of appropriate empirical AMT [58–60]. 
Two studies, Erbay et al. and Harbarth et al., defined the window of time when the 
appropriateness should be evaluated. In the study by Erbay et al., empirical AMT was 
appropriate if at least one antibiotic was active towards the causative pathogen(s) 
within 48 hours after acquisition of the blood culture results [58]. Harbarth et al. 
concluded that AMT was inappropriate if a patient did not receive at least one 
antimicrobial agent to which the causative microorganisms were susceptible within 
24 hours of the diagnosis of severe sepsis [59]. Zaragoza et al. considered empirical 
AMT to be inappropriate if infection was not being effectively treated at the time 
the causative microorganism and its antibiotic susceptibility were known [60].
Six of the studies used relatively simple definitions of inappropriate AMT, whether 
empirical or targeted or both (Table 3.) [58–60, 62, 64–65]. For example, a study 
by Davey et al. defined AMT as inappropriate if the pathogen was resistant to the 
antimicrobial agent used or initiation of the appropriate AMT was delayed [62]. This 
study concluded that if a patient received appropriate empirical AMT and the therapy 
was thereafter promptly targeted, the outcome was better than if the empirical AMT 
25
had been inappropriate but had been switched to appropriate targeted therapy. A 
study by Raineri et al. defined appropriateness versus inappropriateness in the 
following way: AMT was appropriate when the prescribed drug was shown to be 
active (in vitro) against the pathogens and was administrated at adequate doses + 
time intervals, and AMT was inappropriate when the infection was not treated due 
to incorrect antimicrobial choice, presence of resistant pathogens, incorrect dosage, 
incorrect duration or the mycotic infection was not treated [64]. Moreover, Suppli 
et al. defined the appropriate AMT for BSIs to be any therapy with documented 
clinical effect, in vitro activity and a minimum treatment length of 6 days [65]. Other 
studies used more complex and detailed definitions for the appropriateness of AMT 
[61, 63, 66]. Willemsen et al. used a score system to evaluate the appropriateness of 
the AMT [66]. The score system divided the therapies into five different categories: 
correct decision, incorrect decision, incorrect choice, incorrect use and data missing. 
They further speculated that when evaluating incorrect use, the following parameters 
should also be taken into account: dosage, timing, administration and duration of 
therapy. 
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Regarding the choice of antimicrobial, excessive use of vancomycin has been 
reported by several studies. The study by Cosgrove et al. investigated prospectively 
clinicians’ antimicrobial prescriptions for different empirical healthcare infections 
[61]. AMT was criticized in 30% (334/1104) of the cases. In 60/334 (18%) cases, 
unnecessary use of vancomycin was recorded. Patel et al. investigated the use of AMT 
in neonatal infections and likewise recorded frequently inappropriate vancomycin 
use [67]. Vancomycin can be inappropriately used in multiple ways. Common ways 
include prescribing vancomycin unnecessarily for empiric AMT and targeted AMT 
even though there are narrower spectrum and effective antimicrobial(s) available 
[68–71]. The reason for excessive use of vancomycin is not clear. One reason may 
be that many guidelines for empiric therapy include vancomycin, but once the 
data on the pathogen have been exposed, de-escalation is not executed. Increased 
provider awareness of drug-resistant CONS probably also increases the overall use 
of vancomycin. Similar findings have been published by Levy et al. [72]. 
Two studies compared the antimicrobial therapy used to local protocols or 
national guidelines [64, 66], and a study by Borer et al. proposed a standardized 
tool for the assessment of appropriateness of AMT [73]. In a study by Raineri et al., 
a systematic infectious diseases specialist consultation program was implemented 
in the ICU setting. After implementation, adherence to local guidelines regarding 
empirical AMT was increased by more than 20% (63% vs. 84%) [64]. Willemsen et 
al. investigated the appropriateness of AMT and found that during six prevalence 
studies conducted from 2001 to 2004, the appropriateness of AMT did not 
vary a great deal. The appropriateness of AMT was evaluated against the local 
AMT prescription guidelines. Out of 938 patients with AMT, 351 (37%) received 
inappropriate AMT. 
Overall, the proportion of patients receiving inappropriate AMT varied between 
studies. The percentage of patients receiving inappropriate AMT varied (20–24%) 
in empirical AMT [59, 60, 63] and in targeted AMT (16–37%) [63–65]. 
There are a few methodological considerations regarding the literature review 
on appropriate AMT for BSIs or appropriateness of AMT in general. The studies 
included in the review were of adult patients or did not include patients and 
discussing appropriateness of AMT only on a general level (Tables 2. and 3.). 
Research conducted in paediatrics on this area is scarce. Likewise, the number of 
patients in the studies included was relative low, which does not necessarily provide 
enough evidence on what type of evaluation is effective when assessing AMT for BSIs 
or in general. Another concern was that few studies focussed on assessing AMT from 
a narrow point of view, such as covering only one or a few different types of pathogens 
and used AMT for those circumstances. The evaluation of appropriateness of AMT 
in individual patients depends on the pathogens identified, local resistance pattern, 
infection sources, co-morbidities and whether the patient is a child or adult.
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2.2.3.  OUTCOME OF ANTIMICROBIAL THERAPY FOR BLOODSTREAM INFECTIONS
Due to the small number of studies investigating the appropriateness of AMT, it is 
unclear how often inappropriate AMT has been used in the treatment of patients with 
healthcare-associated BSIs. Appropriate empirical AMT for BSI is known to reduce 
the mortality in sepsis [59] and in enterococcal infections [65]. In addition, Erbay et 
al. showed that in bacteremias caused by Acinetobacter baumanii infections, a 26% 
reduction in the overall mortality rate was achieved with adequate early empirical 
antimicrobial therapy compared with inadequate therapy [58]. Similarly, Kumar 
et al. showed that inappropriate empirical AMT in septic shock was associated 
with a fivefold increase in mortality [63]. In addition, Raineri et al. demonstrated 
in patients with different types of serious infections that appropriate AMT was 
associated with decreased mortality [64]. In contrast to these studies, Zaragoza et 
al. showed that inappropriate AMT was not associated with increased mortality 
[60]. This uncommon result was perhaps related to the causative organism(s) or 
origin of the bacteremia.
2.3.  ANTIMICROBIAL THERAPY FOR HOSPITALIZED CHILDREN 
2.3.1.  OFF-LABEL USE OF ANTIMICROBIALS
For market authorization labelling, data on the safety and efficacy of pharmaceuticals 
must be submitted to the regulatory authorities by the pharmaceutical companies. 
Based on the data submitted, a drug can be authorized by the regulatory authorities, 
and the approved labelling, with information on indication and dosing and in 
the age groups the drug has been approved for, is available in the Summary of 
Product Characteristics (SmPC). A drug is used off-label (OL) if it is used in a 
manner not recommended in the SmPC. OL use can be related to age, indication, 
contraindication, dose, age-appropriate formulation and route of administration. 
Dose and formulation (route of administration and ex tempore preparations) are the 
most common OL use categories in children [3, 5–8]. The fact that a drug is used 
OL does not necessarily mean that there is no evidence of its safety and efficacy [74].
The OL use of drugs in children is common [3, 4]. It is estimated that out of 
all pharmaceuticals used in children, approximately 50% are being used OL. The 
frequency of OL use depends on many factors, including point of care (community vs. 
hospital), co-morbidities and age. The use of OL drugs in children’s hospitals varies 
between 12% and 71% [4, 5–12]. In certain groups of patients, such as neonates, 
it can be as high as between 48% and 89% [4–6, 10–11]. In European NICUs 
(Neonatal Intensive Care Units), the prevalence of OL use was between 28% and 
100% [13–16]. Furthermore, in premature neonates the prevalence of OL use is 
known to vary between 91% and 100% [13, 14, 16]. 
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The safety and efficacy of novel antimicrobials (antibacterials, antifungals and 
antivirals) have only seldom been tested in neonates. However, some progress 
has been made after the introduction of the Paediatric Regulation in 2007 [17]. 
The number of clinical trials among neonates has slowly increased. Despite the 
OL use of antimicrobials being relatively uncommon compared to other groups of 
pharmaceuticals, the situation is far from satisfactory [75]. To obtain data on the 
frequency of OL use of antimicrobials in neonates, this use was investigated among 
hospitalized patients.
As the examples discussed above indicate, OL status does not necessarily mean 
that the drug is not safe and effective to use in neonates or children. Research data 
related to dose, efficacy and safety may be available but have not been submitted to 
regulatory authorities for labelling. Age-appropriate dosing recommendations for 
children may be found for some commonly used drugs not labelled for children in 
formularies like BNFC (British National Formulary for Children) and databases such 
as MicromedexR (US). These recommendations are given by clinical professionals, 
and the recommendations are based on academic research and clinical experience. 
However, there are often no clear and exact recommendations for the youngest age 
group, i.e., the premature neonates. Many antimicrobials used OL have established 
their place in the management of infectious diseases in neonates. Despite recent 
positive development in paediatric research, efforts are still needed, particularly 
regarding data on dosing and pharmacokinetics [75]. 
2.3.2.  DOSING AND FORMULATIONS OF ANTIMICROBIALS 
The optimal dosing of many antimicrobials for paediatric patients is not known [3, 
5–8]. In the Children’s Hospital, the most common antimicrobials for BSIs used 
OL (according to Finnish National Drug Formulary, Pharmaca Fennica®) are listed 
in Table 4. Some antimicrobials, despite being on the market for decades, still lack 
official market authorization. As can be seen from Table 4., many commonly used 
antimicrobials do not have dosing recommendations for children. This is especially 
true with neonates.
Due to relatively common OL use of antimicrobials in paediatrics, there are 
not always ready formulations that can be used. Hence, nurses and pharmacists 
prepare formulations suitable for children (ex temporaneous preparations) from 
the formulations aimed at adult use. This exposes children to compromised quality 
of care and medication errors. For example, the amount of dilution added to the 
adult product may not have been calculated correctly. Diluting antimicrobials is 
sometimes necessary in order to administer the drugs intravenously or via other 
routes to a child. A child receiving inappropriately prepared drugs may experience 
overdose or inefficient therapy due to concentrations of the drug that are too low. 
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2.3.3.  ANTIMICROBIAL MEDICATION ERRORS IN CHILDREN
A medication error is an unintended failure in the drug treatment process that 
leads to, or has the potential to lead to, harm to the patient [76]. The frequency 
of medication errors in children is more common than in adults [19]. Moreover, 
when errors occur, children are more prone to clinically significant harm [20]. 
Compared to adults, children are prone to errors for numerous reasons [21]. Many 
drugs lack data on dosing, pharmacokinetics, safety, efficacy and clinical use in 
paediatrics. In addition, many drugs are not authorized for use in paediatrics. This 
leads to a number of issues that compromise paediatric medication safety: lack of 
available dosage forms, individual doses must be calculated based on age, weight 
and/or body surface area, disease(s) and clinical condition. There are few published 
articles focusing on medication errors in paediatrics. Hence, a systematic literature 
review was conducted between January 18th and 20th, 2016, regarding medication 
errors in hospitalized paediatric patients. The search strategy was not aimed solely 
at antimicrobial medication errors but covered all types of medication errors in 
paediatric patients. Altogether, 333 articles were found of which 12 were eligible 
for review according to exclusion and inclusion criteria (Tables 5., 6. and 7. and 
Figure 3.). 
According to the literature review, it has been estimated that medication errors 
are three times more likely to occur in children versus adults [22–33]. Studies 
included in the systematic literature review focused on the different points of process 
where the medication errors occur in paediatrics. The different points were presented 
as follows: prescription errors (5/12 studies), preparation of drugs (1/12 studies), 
administration of drugs (4/12 studies) and all types of medication errors (6/12 
studies) (Table 7.). 
Table 5. Search strategy regarding systematic literature review on medication errors in paediatrics in hospital.
Article sources: Cinahl, Cochrane Library, Medic, Medline (Ovid), Pubmed, Scopus 
Search 
terms
Child* OR Pediatric* 
OR Paediatric
AND Medication error AND Hospital
Additional 
search 
terms
Error report* OR 
Medication error OR 
Incident report* 
AND/OR Patient safe*
Medication safe* 
(safety)
AND/OR High risk 
medication 
or high alert 
medication
Additional 
inclusion 
criteria
English language Human(s) Published between 2000 
and 2016
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Table 6. Exclusion criteria and inclusion criteria for articles accepted for systematic review regarding 
medication errors in paediatrics.
Inclusion criteria Exclusion criteria
Focus of research Children, hospital or medical ward, 
pharmacotherapy
Adults, home or daycare, food, 
nutrition
Type of publication Original research where aim(s), 
methods, results and analysis are 
described
Recommendations not based on 
research, literature reviews, reports, 
expert opinions
Medication error Medication error that either reached 
the patient or was a near miss
Article was solely focused on adverse 
effects
Prevention of 
medication errors
New method has been invented and 
the functionality of the method is 
being tested
Other safety issues besides medicine-
related are investigated, such as patient 
safety overall or safety of equipment
Availability Article was fully available without 
any costs via University of Helsinki’s 
library or via Internet (open access)
Article not available without costs via 
University of Helsinki library 
Patients included in the studies were from different kinds of wards in 5/12 studies, 
in ICU/PICU/NICU in 4/12 studies, in GEN in 3/12 studies, were oncology patients 
in 2/12 studies and were patients of SURG in one study (Table 7). 
The prevalence of reported medication errors in children’s hospitals varied 
between 13–19% [25, 26, 28, 30]. Administration errors were commonly identified 
with an 18–19% occurrence [21, 24]. Prevalence of omission errors were likewise 
relatively common ranging between 12–23% [23, 26, 33]. Doses that were too high 
were identified by many studies, with prevalence ranging from 12–24% [24, 33, 
40]. Look-alike and sound-alike (LASA) medicines were involved in 36% of cases 
of incorrect medication [30]. The causes of medication errors were reported as the 
following: communication (20–34%) and lack of following policy or procedures 
(22–41%) [30, 33]. In addition, nurses reported excessive work load and distractions 
that undermine the quality of care [29]. Several studies reported that despite the 
relatively high occurrence of medication errors, none of them were identified as 
leading to permanent injury or severe clinical harm [24, 25, 30]. One study did, 
however, report an incidence rate of 0.1% in errors causing severe harm [31].
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ro
ng
 in
fu
sio
n 
sp
ee
d 
an
d 
pr
es
cr
ip
tio
n 
er
ro
r o
r 
om
iss
io
n 
er
ro
r.
Th
is 
stu
dy
 h
el
pe
d 
pr
ov
id
e 
im
po
rta
nt
 
in
fo
rm
at
io
n 
ab
ou
t t
he
 ra
te
 a
nd
 
ep
id
em
io
lo
gy
 o
f m
ed
ic
at
io
n 
er
ro
rs
, 
em
ph
as
iz
in
g 
on
 th
e 
ro
le
 o
f a
ud
it 
in
 
en
ab
lin
g 
de
ve
lo
pm
en
t o
f a
pp
ro
pr
ia
te
 
er
ro
r-r
ed
uc
in
g 
str
at
eg
ie
s, 
pa
rti
cu
la
rly
 
in
 th
e 
co
nt
ex
t o
f q
ua
lit
y 
as
su
ra
nc
e 
in
 
ho
sp
ita
ls.
G
ha
le
b 
et
 a
l. 
20
09
U
K
To
 e
va
lu
at
e 
w
ha
t t
yp
e 
pf
 
m
ed
ic
at
io
n 
er
ro
rs
 o
cc
ur
 
w
he
n 
pr
es
cr
ib
in
g 
an
d 
ad
m
in
ist
er
in
g 
dr
ug
s b
y 
us
in
g 
qu
an
tit
at
iv
e 
an
d 
qu
al
ita
tiv
e 
m
et
ho
ds
.
P,
 R
E
D
IF
FE
RE
N
T 
W
A
RD
S 
fro
m
 5
 
ho
sp
ita
ls 
Tw
o 
w
ee
k 
da
ta
 
co
lle
ct
io
n
29
55
 
pr
es
cr
ip
tio
ns
 
w
er
e 
ev
al
ua
te
d 
an
d 
22
49
 
ad
m
in
ist
ra
tio
n 
of
 d
ru
gs
 w
er
e 
ob
se
rv
ed
-p
re
sc
rip
tio
n
-a
dm
in
ist
ra
tio
n
39
1 
pr
es
cr
ip
tio
n 
er
ro
rs
 (1
3.
,2
%
). 
M
os
t t
yp
ic
al
 e
rro
rs
 re
ga
rd
in
g 
pr
es
cr
ip
ti
on
s 
w
er
e:
 in
su
ffi
ci
en
t 
pr
es
cr
ip
tio
n 
(m
iss
in
g 
so
m
et
hi
ng
 
su
ch
 a
s a
dm
in
ist
ra
tio
n 
ro
ut
e)
, u
se
 o
f 
ab
br
ev
ia
tio
ns
 a
nd
 w
ro
ng
 d
os
e.
42
9 
ad
m
in
ist
ra
tio
n 
er
ro
rs
. 
M
os
t t
yp
ic
al
 e
rro
rs
 re
ga
rd
in
g 
ad
m
in
ist
ra
tio
n 
w
er
e:
 p
re
pa
rin
g 
of
 
th
e 
dr
ug
, w
ro
ng
 a
dm
in
ist
ra
tio
n 
ro
ut
e 
w
ith
 i.
v.
 d
ru
gs
 a
nd
 w
ro
ng
 ti
m
in
g.
S
ig
ni
fi
ca
nt
 d
iff
er
en
ce
 r
eg
ar
di
ng
 
pr
es
cr
ip
tio
n 
er
ro
rs
 b
et
w
ee
n 
w
ar
ds
 
w
as
 d
et
ec
te
d.
 R
oo
t c
au
se
s s
ho
ul
d 
be
 
an
al
ys
ed
. 
O
bs
er
ve
d 
m
ed
ic
at
io
n 
er
ro
rs
 w
er
e 
co
m
pa
re
d 
to
 e
rro
r r
eg
ist
ry
 a
nd
 w
he
n 
ob
se
rv
in
g,
 m
or
e 
m
ed
ic
at
io
n 
er
ro
rs
 
w
er
e 
de
te
ct
ed
. H
en
ce
, e
rro
rs
 a
re
 
un
de
r r
ep
or
te
d.
 
Pr
es
cr
ib
in
g 
an
d 
m
ed
ic
at
io
n 
ad
m
in
ist
ra
tio
n 
er
ro
rs
 a
re
 n
ot
 
un
co
m
m
on
 in
 p
ae
di
at
ric
s, 
pa
rtl
y 
as
 a
 re
su
lt 
of
 th
e 
ex
tra
 c
ha
lle
ng
es
 
in
 p
re
sc
rib
in
g 
an
d 
ad
m
in
ist
er
in
g 
m
ed
ic
at
io
n 
to
 th
is 
pa
tie
nt
 g
ro
up
. 
Th
e 
ca
us
es
 a
nd
 e
xt
en
t o
f t
he
se
 e
rro
rs
 
ne
ed
 to
 b
e 
ex
pl
or
ed
 lo
ca
lly
 a
nd
 
im
pr
ov
em
en
t s
tra
te
gi
es
 p
ur
su
ed
.
41
Fe
rn
án
de
z-
Ll
am
az
ar
es
et
 a
l.
20
13
Sp
ai
n
To
 d
es
cr
ib
e 
w
ha
t s
or
t 
of
 p
re
sc
rip
tio
n 
er
ro
rs
 
ph
ar
m
ac
ist
s c
an
 d
et
ec
t 
an
d 
ho
w
 th
es
e 
er
ro
rs
 
co
ul
d 
be
 p
re
ve
nt
ed
 a
nd
 
ho
w
 to
 re
co
gn
ise
 m
os
t 
co
m
m
on
 e
rro
r t
yp
es
.
P,
 D
D
IF
FE
RE
N
T 
W
A
RD
S
Ei
gh
t h
os
pi
ta
ls 
in
cl
ud
ed
. 
-p
re
sc
rip
tio
n
64
6 
in
te
rv
en
tio
ns
 re
la
te
d 
to
 
qu
al
ity
 o
f t
he
 p
re
sc
rip
tio
n 
w
er
e 
in
cl
ud
ed
. 4
1.
2  
%
 c
on
ce
rn
ed
 m
an
ua
l 
pr
es
cr
ib
in
g 
sy
ste
m
s, 
an
d 
58
.8
 %
 
el
ec
tro
ni
c 
pr
es
cr
ib
in
g 
sy
ste
m
s. 
In
 
in
te
rv
en
tio
ns
 c
on
ce
rn
in
g 
pr
es
cr
ib
in
g 
er
ro
rs
, 2
12
 d
iff
er
en
t d
ru
gs
 w
er
e 
in
vo
lv
ed
, m
ai
nl
y 
be
lo
ng
in
g 
to
 
th
e 
gr
ou
p 
of
 a
nt
i-i
nf
ec
tiv
es
. M
ai
n 
pr
es
cr
ip
tio
n 
er
ro
rs
 a
re
 d
os
in
g 
er
ro
rs
 
(4
9.
3 
%
). 
51
.9
 %
 (3
06
 c
as
es
) w
er
e 
co
ns
id
er
ed
 s
ig
ni
fi
ca
nt
, 2
6.
3 
%
 
(1
55
 c
as
es
) 
of
 m
in
or
 s
ig
ni
fi
ca
nc
e,
 
19
.8
 (1
17
 c
as
es
) w
er
e 
cl
in
ic
al
ly
 
se
rio
us
 a
nd
 2
.0
 %
 (1
2 
ca
se
s)
 w
er
e 
po
te
nt
ia
lly
 fa
ta
l. 
Th
e 
im
pa
ct
 o
f 
ac
ce
pt
ed
 in
te
rv
en
tio
ns
 sh
ow
ed
 th
at
 
64
.7
 %
 h
ad
 a
 s
ig
ni
fi
ca
nt
 im
pa
ct
 o
n 
pa
tie
nt
 h
ea
lth
 o
ut
co
m
e,
 h
ig
hl
ig
ht
in
g 
1.
1 
%
 w
it
h 
a 
hi
gh
ly
 s
ig
ni
fi
ca
nt
 
im
pa
ct
. T
he
 a
ct
iv
ity
 le
ve
l o
f t
he
 
pa
ed
ia
tri
c 
cl
in
ic
al
 p
ha
rm
ac
ist
s w
as
 
hi
gh
ly
 v
ar
ia
bl
e,
 w
ith
 a
 m
ed
ia
n 
of
 
0.
01
4 
in
te
rv
en
tio
ns
/b
ed
-d
ay
 d
ur
in
g 
th
e 
da
ta
 c
ol
le
ct
io
n 
pe
rio
d.
 
In
 v
ie
w
 o
f t
he
 im
po
rta
nc
e 
of
 th
e 
do
sin
g 
er
ro
rs
 in
 th
e 
pr
es
cr
ip
tio
n 
ph
as
e,
 a
nd
 th
e 
cl
in
ic
al
 re
le
va
nc
e 
of
 
th
e 
er
ro
rs
 d
et
ec
te
d,
 it
 se
em
s t
o 
be
 
ne
ce
ss
ar
y 
to
 im
pl
em
en
t m
ea
su
re
s 
as
 th
e 
de
ve
lo
pm
en
t o
f d
ec
isi
on
 
su
pp
or
t s
ys
te
m
s f
or
 p
ae
di
at
ric
 
do
sin
g 
an
d 
str
en
gt
he
n 
th
e 
pr
es
en
ce
 
of
 p
ha
rm
ac
ist
s a
s a
 k
ey
 e
le
m
en
t i
n 
pr
ev
en
tin
g 
pr
es
cr
ib
in
g 
er
ro
rs
 fr
om
 
re
ac
hi
ng
 p
at
ie
nt
s, 
th
us
 e
ns
ur
in
g 
th
at
 
ch
il
dr
en
 r
ec
ei
ve
 e
ff
ec
ti
ve
, s
af
e 
an
d 
effi
ci
en
t d
ru
g 
th
er
ap
y.
M
an
ia
s 
et
 a
l.
20
14
 
A
us
tr
al
ia
To
 d
es
cr
ib
e 
th
e 
pr
ev
al
en
ce
 a
nd
 q
ua
lit
y 
of
 m
ed
ic
at
io
n 
er
ro
rs
 a
nd
 
pr
ed
isp
os
in
g 
fa
ct
or
s i
n 
ho
sp
ita
l.
R,
 R
E
A
LL
 W
A
RD
S
du
rin
g 
4 
ye
ar
s 
-a
ll 
ty
pe
s o
f 
er
ro
rs
27
53
 m
ed
ic
at
io
n 
er
ro
rs
 w
er
e 
re
po
rte
d.
 T
he
 m
os
t c
om
m
on
 e
rro
rs
 
w
er
e:
 d
os
e 
ca
lc
ul
at
ed
 w
ro
ng
, t
oo
 
hi
gh
 d
os
e 
gi
ve
n,
 o
m
iss
io
n 
of
 a
 d
ru
g 
an
d 
w
ro
ng
 te
ch
ni
qu
e 
re
ga
rd
in
g 
ad
m
in
ist
ra
tio
n 
of
 i.
v.
 d
ru
gs
.
Th
e 
im
po
rta
nc
e 
of
 c
om
m
un
ic
at
io
n 
is 
re
le
va
nt
 e
sp
ec
ia
lly
 w
he
n 
ch
ild
 is
 
tra
ns
fe
rre
d 
to
 a
no
th
er
 m
ed
ic
al
 w
ar
d.
42
2. Review of the literature
N
ie
m
an
 
et
 a
l.
20
14
 
G
er
m
an
y
To
 p
re
ve
nt
 m
ed
ic
at
io
n 
er
ro
rs
 in
 p
ae
di
at
ric
 
w
ar
ds
. P
ha
rm
ac
ist
s 
m
on
ito
re
d 
dr
ug
 h
an
dl
in
g 
by
 n
ur
se
s p
rio
r t
o 
an
d 
fo
llo
w
in
g 
ea
ch
 
in
te
rv
en
tio
n 
ste
p.
I
O
ne
 p
ae
di
at
ric
 
w
ar
d
-e
rro
rs
 re
la
te
d 
to
 
dr
ug
 h
an
dl
in
g
Th
e 
nu
m
be
r o
f p
at
ie
nt
s w
ho
 
w
er
e 
su
bj
ec
te
d 
to
 a
t l
ea
st 
on
e  
m
ed
ic
at
io
n 
er
ro
r i
n 
dr
ug
 
ha
nd
lin
g 
de
cr
ea
se
d 
fro
m
 3
8/
43
 
(8
8%
) t
o 
25
/5
1 
(4
9%
) f
ol
lo
w
in
g 
th
e 
th
ird
 in
te
rv
en
tio
n,
 a
nd
 th
e 
ov
er
al
l 
fre
qu
en
cy
 o
f e
rro
rs
 d
ec
re
as
ed
 fr
om
 
52
7 
er
ro
rs
 in
 5
81
 p
ro
ce
ss
es
 (9
1%
) 
to
 1
16
/4
41
 (2
6%
). 
Th
e 
iss
ue
 o
f t
he
 
ha
nd
ou
t r
ed
uc
ed
 m
ed
ic
at
io
n 
er
ro
rs
 
ca
us
ed
 b
y 
kn
ow
le
dg
e 
de
fi
ci
ts
 
re
ga
rd
in
g,
 fo
r i
ns
ta
nc
e,
 th
e 
co
rre
ct
 
“‘
vo
lu
m
e 
of
 so
lv
en
t f
or
 IV
 d
ru
gs
”’
 
fro
m
 4
9-
25
%
. I
nt
er
ve
nt
io
ns
 re
du
ce
d 
m
ed
ic
at
io
n 
er
ro
rs
 s
ig
ni
fi
ca
nt
ly
. 
Pa
ed
ia
tri
c 
dr
ug
 h
an
dl
in
g 
is 
pr
on
e 
to
 e
rro
rs
. A
 th
re
e-
ste
p 
in
te
rv
en
tio
n 
eff
ec
ti
ve
ly
 d
ec
re
as
ed
 th
e 
hi
gh
 
fre
qu
en
cy
 o
f m
ed
ic
at
io
n 
er
ro
rs
 b
y 
ad
dr
es
sin
g 
th
e 
di
ve
rs
ity
 o
f t
he
ir 
ca
us
es
.
R
in
ke
 
et
 a
l. 
20
08
U
S
To
 d
es
cr
ib
e 
th
e 
pr
ev
al
en
ce
 a
nd
 q
ua
lit
y 
of
 
pr
es
cr
ip
tio
n 
m
ed
ic
at
io
n 
er
ro
rs
 in
 m
ed
ic
al
 w
ar
ds
 
an
d 
cl
in
ic
s i
n 
or
de
r t
o 
de
ve
lo
p 
m
ed
ic
at
io
n 
sa
fe
ty
.
To
 d
isc
ov
er
 w
he
th
er
 a
 
cl
in
ic
al
 p
ha
rm
ac
ist
 a
t t
he
 
m
ed
ic
al
 w
ar
ds
 w
ou
ld
 
be
 u
se
fu
l i
n 
re
du
ci
ng
 
m
ed
ic
at
io
n 
er
ro
rs
.
R,
 Q
, Q
N
, 
RE
D
IF
FE
RE
N
T 
W
A
RD
S.
 D
at
a 
fro
m
 2
00
5 
du
rin
g 
17
 d
ay
s a
nd
 6
 
m
on
th
s p
er
io
ds
.
-p
re
sc
rip
tio
n
47
/ o
f 3
77
 (1
2.
5%
) i
n-
ho
us
e 
or
de
rs
 
an
d 
37
/ o
f 1
91
 (1
9.
4%
) i
nd
iv
id
ua
l 
ch
ar
ts 
co
nt
ai
ne
d 
at
 le
as
t 1
 e
rro
r: 
4 
(1
.1
%
) o
rd
er
s c
on
ta
in
ed
 a
n 
in
co
rre
ct
 
do
se
, 4
1 
(1
0.
8%
) w
er
e 
w
rit
te
n 
in
co
rre
ct
ly
 a
nd
 2
 (0
.5
%
) c
on
ta
in
ed
 
an
 in
co
rre
ct
 d
os
e 
an
d 
w
er
e 
w
rit
te
n 
in
co
rre
ct
ly
.  
D
ru
gs
 m
os
t o
fte
n 
as
so
ci
at
ed
 w
ith
 m
ed
ic
at
io
n 
er
ro
rs
 
w
er
e 
m
or
ph
in
e,
 a
ce
ta
m
in
op
he
n,
 
ib
up
ro
fe
n 
(in
 th
e 
m
ed
ic
al
 w
ar
ds
) 
an
d 
am
ox
ic
ill
in
, i
bu
pr
of
en
, 
di
ph
en
hy
dr
am
in
e 
(in
 c
lin
ic
s)
.
Pr
es
cr
ib
in
g 
er
ro
rs
 a
re
 c
om
m
on
 in
 
bo
th
 w
rit
te
n 
in
-h
ou
se
 o
rd
er
s a
nd
 
am
bu
la
to
ry
 p
re
sc
rip
tio
ns
 in
 a
 P
ED
. 
Ta
rg
et
in
g 
sa
fe
ty
 in
te
rv
en
tio
ns
 
to
w
ar
d 
gr
ou
ps
 w
ith
 le
ss
 p
ra
ct
ic
e 
in
 
pr
es
cr
ib
in
g 
pa
ed
ia
tri
c 
do
se
s a
nd
 re
-
ed
uc
at
in
g 
gr
ou
ps
 o
n 
sa
fe
 m
ed
ic
at
io
n 
w
rit
in
g 
te
ch
ni
qu
es
 c
ou
ld
 d
ec
re
as
e 
th
is 
er
ro
r r
at
e.
Sh
aw
et
 a
l.
20
12
U
S
To
 d
es
cr
ib
e 
m
ed
ic
at
io
n 
er
ro
rs
 in
 P
IC
U
s. 
D
ev
el
op
 
a 
sta
nd
ar
di
ze
d 
sy
ste
m
 
fo
r t
he
 a
na
ly
sis
 o
f 
m
ed
ic
at
io
n 
er
ro
rs
.
R,
 Q
, R
E
18
 P
IC
U
s a
nd
 
m
ed
ic
at
io
n 
er
ro
rs
 in
 th
os
e 
w
er
e 
co
lle
ct
ed
 
be
tw
ee
n 
20
07
 
an
d 
20
08
.
-a
ll 
ty
pe
s o
f 
m
ed
ic
at
io
n 
er
ro
rs
59
7 
m
ed
ic
at
io
n 
er
ro
rs
 re
po
rte
d.
 
M
os
t c
om
m
on
 ty
pe
 o
f m
ed
ic
at
io
n 
er
ro
rs
 w
er
e 
w
ro
ng
 d
os
e 
(3
9%
), 
w
ro
ng
 m
ed
ic
at
io
n 
(1
7%
) a
nd
 
de
la
ye
d 
or
 m
iss
ed
 d
os
e 
(1
6%
). 
M
os
t 
co
m
m
on
ly
 in
vo
lv
ed
 m
ed
ic
in
es
 w
er
e 
an
ti-
in
fe
ct
iv
es
 (2
5%
), 
an
al
ge
sic
s 
(2
1%
),
 in
tr
av
en
ou
s 
fl
ui
ds
 (
12
%
) 
an
d 
re
sp
ira
to
ry
 (1
1%
). 
13
%
 o
f r
ec
or
de
d 
er
ro
rs
 w
er
e 
as
so
ci
at
ed
 w
ith
 n
on
-fa
ta
l 
ha
rm
 to
 th
e 
pa
tie
nt
. 
Re
po
rti
ng
 b
y 
th
e 
sy
ste
m
 re
ve
al
ed
 
va
lu
ab
le
 d
at
a 
ac
ro
ss
 si
te
s o
n 
m
ed
ic
at
io
n 
ca
te
go
rie
s a
nd
 
po
te
nt
ia
l h
um
an
 fa
ct
or
s. 
H
ar
m
 w
as
 
in
fre
qu
en
tly
 re
po
rte
d.
 O
ur
 a
na
ly
se
s 
id
en
tif
y 
tre
nd
s a
nd
 la
te
nt
 sy
ste
m
s 
iss
ue
s, 
su
gg
es
tin
g 
ar
ea
s f
or
 fu
tu
re
 
in
te
rv
en
tio
ns
 to
 re
du
ce
 p
ae
di
at
ric
 
m
ed
ic
at
io
n 
er
ro
rs
.
43
Se
ar
s 
et
 a
l.
20
12
 
C
an
ad
a
To
 d
efi
ne
 w
ha
t f
ac
to
rs
 
co
nt
rib
ut
e 
to
 m
ed
ic
at
io
n 
er
ro
rs
.
S
D
IF
FE
RE
N
T 
W
A
RD
S 
fro
m
 
di
ff
er
en
t s
ec
ti
on
s 
of
 C
an
ad
a.
 .
-a
ll 
ty
pe
s o
f 
m
ed
ic
at
io
n 
er
ro
rs
12
7 
po
te
nt
ia
l a
nd
 2
45
 a
ct
ua
l 
m
ed
ic
at
io
n 
er
ro
rs
 re
po
rte
d.
M
os
t c
om
m
on
ly
 re
po
rte
d 
m
ed
ic
at
io
n 
er
ro
rs
: w
ro
ng
 ti
m
in
g 
of
 th
e 
dr
ug
, 
w
ro
ng
 d
os
e,
 a
nd
 w
ro
ng
 m
ed
ic
in
e.
Th
e 
ne
xt
 st
ep
 is
 to
 e
xp
lo
re
 h
ow
 
er
ro
rs
 o
cc
ur
 w
ith
in
 th
e 
en
tir
e 
m
ed
ic
at
io
n 
de
liv
er
y 
pr
oc
es
s. 
Th
e 
la
ck
 o
f s
ta
nd
ar
di
za
tio
n 
ha
s l
ea
d 
to
 a
 
pa
uc
ity
 o
f c
om
pa
ra
bi
lit
y 
ac
ro
ss
 si
te
s 
an
d 
stu
di
es
 th
at
 in
 tu
rn
 h
av
e 
re
du
ce
d 
th
e 
ad
va
nc
em
en
t o
f 
re
se
ar
ch
 fi
nd
in
gs
 
in
 th
is 
ar
ea
. 
Sn
ijd
er
s 
et
 a
l.
20
07
N
et
he
rl
an
ds
To
 e
va
lu
at
e 
re
po
rte
d 
m
ed
ic
at
io
n 
er
ro
rs
 a
nd
 to
 
id
en
tif
y 
w
ha
t t
yp
es
 o
f 
er
ro
rs
 a
re
 m
os
t r
isk
y 
at
 
N
IC
U
.
P,
 S
10
 N
IC
U
s 
an
d 
on
e 
IC
U
 
w
ar
d 
w
he
re
 
m
ed
ic
at
io
n 
er
ro
r 
re
po
rts
 w
er
e 
ev
al
ua
te
d 
du
rin
g 
7 
m
on
th
s. 
-a
ll 
ty
pe
s o
f 
m
ed
ic
at
io
n 
er
ro
rs
48
46
 in
ci
de
nt
 re
po
rts
 (n
ot
 a
ll 
re
la
te
d 
to
 m
ed
ic
at
io
n 
er
ro
rs
) t
ha
t e
nt
ai
le
d 
na
rra
tiv
e 
pa
rt 
as
 w
el
l a
s m
ul
tip
le
 
ch
oi
ce
 q
ue
sti
on
s r
eg
ar
di
ng
 c
lin
ic
al
 
si
gn
ifi
ca
nc
e 
of
 th
e 
er
ro
r. 
R
ep
or
te
d 
in
ci
de
nt
s c
on
ce
rn
in
g 
m
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Two studies identified antimicrobial errors as one of the most common medication 
errors of all the drug classes used [28, 30]. More specific information regarding 
antimicrobial errors in paediatrics is definitely needed since antimicrobials, together 
with analgesics, are the most frequently consumed drugs in hospitals. 
2.4.  PRUDENT USE OF ANTIMICROBIALS
2.4.1.  RESISTANCE TOWARDS ANTIMICROBIALS  
Pathogens, such as bacteria, viruses and fungi, can develop resistance towards 
antimicrobials [77]. Resistance can be developed by multiple mechanisms, and as 
a result of such development the pathogens are either partly or entirely resistant to 
given antimicrobials. Numbers of resistant pathogens are unfortunately constantly 
increasing, which necessitates the prudent use of antimicrobials. According to the 
Centers for Disease Control and Prevention (CDC), the most threatening resistant 
bacteria are carbapenem-resistant Enterobacteriaceae (CRE), methicillin-resistant 
Staphylococcus aureus (MRSA), ESBL-producing Enterobacteriaceae (extended-
spectrum β-lactamases), vancomycin-resistant Enterococcus (VRE), multidrug-
resistant Pseudomonas aeruginosa and multidrug-resistant Acinetobacter [78]. 
Due to these threats, in 2017 the WHO published a list of bacteria for which new 
antibiotics are urgently needed to combat the infections. All of these so-called 
high-priority bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa and 
Enterobacteriaeceae) are carbapenem-resistant and Enterobacteriaeceae are 
likewise ESBL-enzyme producing [78]. In general, this means that beta-lactam 
antibacterials are no longer effective against these resistant pathogens. All of these 
critical, high-priority bacteria can cause lethal invasive infections. Hence, the growing 
resistance is alarming since carbapenems and third-generation cephalosporins have 
been the most efficient drugs against multi-drug resistant bacteria. ASPs are being 
implemented in order to tackle the alarming growth of antimicrobial resistance.
2.4.2.  ANTIMICROBIAL STEWARDSHIP PROGRAMS IN HOSPITALS 
Antimicrobial stewardship programs (ASPs) in hospitals are aimed at reducing the 
unnecessary use of excessively broad-spectrum antimicrobials in order to restrict 
these drugs to situations where they are the only effective treatment. Likewise, 
optimizing patient outcomes and minimizing the probability of adverse effects 
are a high priority. According to the CDC, the core elements of ASPs include the 
following: involving leaders, using physicians as leaders, appointment of pharmacists 
for developing and improving antimicrobial use, taking actions such as evaluating 
ongoing processes regarding antimicrobial therapies, monitoring the prescribing 
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and resistance of antimicrobials, reporting of antimicrobial use to healthcare 
professionals and educating healthcare professionals on resistance and clinicians 
on prescribing [80]. ASPs have been successful globally [81], and these programs 
have been applied in Finland as well, with a typical example being surveillance of 
antimicrobial resistance patterns [82]. 
The key factors regarding successful ASPs and interventions that improve 
appropriate use of antimicrobials have been investigated by multiple good-quality 
studies with large data or high-quality expert panels involved [83–91]. Davey et al. 
conducted a systematic review regarding antibiotic prescribing patterns and how 
inappropriate patterns could be influenced by using either restrictive techniques or 
enabling techniques [85]. Interventions with enabling techniques offering feedback 
for the prescriber were considered more effective compared to restrictive interventions 
only, such as controlled antimicrobial lists. Dellit et al. proposed a list of activities that 
could be prioritized depending on the institute at hand [86]. These elements include 
education, guidelines and clinical pathways, antimicrobial order forms, combination 
therapy, streamlining or de-escalation of therapy, dose optimization and parenteral 
to oral conversion. Systematic review by Schuts et al. offers an evidence-based list on 
of key measures assuring the prudent use of antimicrobials [90]. This list includes 
five core elements: 1) empirical treatment according to local or national guidelines, 
2) de-escalation of treatment, 3) parenteral-to-oral switch, 4) therapeutic drug 
monitoring and 5) restricted antimicrobial lists. The Transatlantic Taskforce on 
Antimicrobial Resistance (TATFAR) introduced a process for common structure 
indicators for hospital ASPs [91]. They discovered that a functional ASP needs a 
suitable infrastructure, appropriate practice and policy measures, and monitoring 
and feedback elements in order to be effective. Regarding paediatric hospitals, a 
study by Nichols et al. introduced several core elements for paediatric ASPs and 
stated that pharmacists educated in infectious diseases and paediatrics should be 
involved in these programs as part of a multidisciplinary team [92]. 
2.4.3.  MONITORING ANTIMICROBIAL CONSUMPTION IN CHILDREN’S HOSPITALS
Investigating and monitoring the consumption of antimicrobials in hospitals is 
necessary in order to encourage prudent use of these drugs. The use of broad-
spectrum antibacterials is a potential problem. It causes selection pressure and 
may lead to increasing numbers of resistant pathogens. In addition, such use of 
antibacterials probably also causes difficult secondary infections [93, 94]. Similarly, 
local knowledge of the use of antimicrobials is crucial and allows us to implement 
necessary measures to support appropriate use of antimicrobials. 
When investigating the consumption of antimicrobials, Defined Daily Doses 
(DDDs) can be used. DDD is the assumed average maintenance dose per day for 
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a drug used for its main indication in adults [95, 96]. Numerous studies have 
investigated the consumption of antimicrobials in hospitalized adult patients by 
using DDDs [97–100], but there are few studies in paediatric patients. 
There are obvious obstacles when using DDDs in children, the most important 
being that the paediatric population is a very heterogeneous group with great 
variation in weight and age. Thus, comparing neonatal use with that of adolescents 
is very challenging. The DDDs may, however, be used to describe paediatric 
consumption of individual antimicrobials over a certain period of time in a setting 
where no major changes in the hospital clientele took place. 
Measuring the consumption of antimicrobials is recommended by the WHO 
[101]. Monitoring of antibiotic use is also a prerequisite of local control of these 
pharmaceuticals. According to a Cochrane review, interventions to reduce excessive 
antibiotic prescribing to hospital inpatients can reduce antimicrobial resistance or 
hospital-acquired infections, and interventions to increase effective prescribing can 
improve clinical outcomes [102].
Consumption of antibacterials in Finnish hospitals in adults and children has 
been relatively moderate when compared to other European countries [103]. The 
most commonly used group of antibacterials are beta-lactams, since they are well 
tolerated and efficient against several pathogens causing community-acquired 
paediatric infections such pneumococci, meningococci and streptococci. In a recent 
study of 32 European paediatric hospitals, the most commonly used antimicrobials 
were ceftriaxone, ampicillin, cefuroxime and oral amoxicillin [104]. 
Whether or not the DDDs represent actual use of antimicrobials in paediatrics, 
i.e., prescription daily doses (PDDs), has been widely discussed. The PDDs of a drug 
give the amount of the drug that actually has been prescribed. DDDs represent 
the daily use of a drug for its main indication with its average dose. If the drug 
is used for other purposes besides its main indication or with another dose, it is 
not equivalent to the DDDs. One study suggests that there is a strong correlation 
between DDDs and PDDs [105]. However, others have concluded that there are 
differences between the two [106–108]. 
Despite these difficulties, many studies investigating the consumption of 
antimicrobials in DDDs in children [109–112] have been published. A review 
regarding ways of measuring antimicrobial consumption concluded that to date 
there are no ideal ways of measuring the consumption of antimicrobials in children 
[113]. Fortin et al. concluded that the most frequently used method of measuring 
antimicrobial consumption in paediatrics was the use of DDDs, which was applied 
by 42% of studies. Currently, the WHO does not recommend the use of DDDs 
as a measurement in children, but in practice this approach is commonly used 
since more accurate methods are not available [114]. Thus, there are no generally 
accepted DDDs for children, although some studies have suggested possible DDDs 
for different ages of children [115, 116]. 
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At the moment, there is an obvious need for the development of novel means of 
measuring antimicrobial use in paediatric patients. One possible way of producing 
such data would be based on the weight of individual patients. The study by Porta 
et al. in 2012 (European ARPEC project) suggested age-appropriate DDDs for 
antibiotics, especially for neonates [115]. On the other hand, some studies suggest 
that adult DDDs in paediatrics may be equal with PDDs or higher [104, 117]. 
2.5.  CONCLUSION
Based on the literature reviews and literature searches, there are a great deal of gaps 
regarding AMT in hospitalized children, both globally and locally in the Children’s 
Hospital, Helsinki University Hospital. For many areas of interest, there are no 
studies conducted in paediatrics or the evidence is scarce (Table 8.). 
Table 8. Current gaps regarding antimicrobial therapy (AMT) in hospitalized paediatric patients in literature 
and issues investigated by this thesis via four studies. 
Gap identified Study addressing issue
Globally no studies found on addressing evaluating the appropriateness of 
AMT for blood culture positive infections in paediatrics
Study I
Existing literature provides research on how to investigate antimicrobial 
consumption in children’´s hospitals but the Children’´s Hospital, Helsinki 
University Hospital has not investigated it´s own antimicrobial use and 
resistance patterns in a concisively comprehensive manner over a long 
period of time
Study II 
Existing literature provides some information regarding what antimicrobials 
are classified OL (off-label) in Finland vs. abroad, but information is needed 
about the current practices in the Children’´s Hospital, Helsinki University 
Hospital
Study III
Globally scarce information on antimicrobial medication errors in 
paediatrics
Study IV
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3. AIMS OF THE THESIS
The purpose of this study was to obtain detailed information on the use of 
antimicrobials in the tertiary Children’s Hospital, Helsinki University Hospital, in 
order to support prudent, safe and efficient use of antimicrobials (Figure 4).
The aims of the studies were as follows:
1) To evaluate the appropriateness of AMT in children with blood culture positive 
infections (I)
2) To investigate the consumption of antimicrobials in the hospital in Defined Daily 
Doses (II)
3) To record the prevalence of off-label use of antimicrobials in neonates (III) 
4) To analyse actual antimicrobial medication errors (IV)
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Figure 4. The studies (I-IV) included in the thesis. AMT=antimicrobial therapy, OL=off-label use. 
Use of 
antimicrobials 
in the 
Children's 
Hospital
I 
Appro-
priateness of 
AMT in 
individual 
patients
II 
Consumption 
of anti-
microbials in 
the hospital
III
OL use of 
anti-
microbials in 
neonates
IV
Anti-
microbial 
medication 
errors
Figure 4. The studies (I–IV) included in the thesis. AMT=antimicrobial therapy, OL=off-label use.
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4. MATERIALS AND METHODS
4.1. STUDY CONTEXT AND DESIGN
This study applied both prospective and retrospective data collection and both 
qualitative and quantitative methods, design and analysis of the data in order to 
investigate the use of antimicrobials in the Children’s Hospital. Multiple data sources 
and different types of methods were applied in this thesis to provide a comprehensive 
and deep understanding of the appropriate use of these drugs (Table 9.).
50
4. Materials and methods
Ta
bl
e 
9.
 M
at
er
ia
ls
 a
nd
 m
et
ho
ds
 u
se
d 
in
 s
tu
di
es
 I–
IV
.
St
ud
y
St
ud
y 
de
sc
ri
pt
io
n
D
at
a 
co
lle
ct
io
n 
ye
ar
(s
)
Pa
tie
nt
 (N
)/ 
R
eg
ist
ry
 (R
E)
 
da
ta
D
at
a 
so
ur
ce
s u
til
iz
ed
M
et
ho
ds
 a
nd
 a
na
ly
sis
I
A
na
ly
sis
 o
f p
at
ie
nt
 re
co
rd
s o
f p
at
ie
nt
s w
ith
 
bl
oo
d 
cu
ltu
re
 p
os
iti
ve
 in
fe
ct
io
ns
 a
nd
 A
M
T 
fo
r 
th
e 
in
fe
ct
io
n
20
05
–2
01
2
N
=1
49
-H
os
pi
ta
l i
nf
ec
tio
ns
 d
at
ab
as
e
-E
le
ct
ro
ni
c 
pa
tie
nt
 re
co
rd
s i
n 
M
ira
nd
a 
pr
og
ra
m
-W
eb
La
b 
la
bo
ra
to
ry
 re
su
lts
-H
an
d 
w
rit
te
n 
pa
tie
nt
 re
co
rd
s
R 
+ 
Q
U
A
L 
II
Su
rv
ei
lla
nc
e 
of
 e
le
ct
ro
ni
c 
re
co
rd
s o
n 
an
tim
ic
ro
bi
al
 c
on
su
m
pt
io
n 
in
 C
hi
ld
re
n’
s 
H
os
pi
ta
l
20
03
–2
01
3
RE
H
U
CH
 H
os
pi
ta
l P
ha
rm
ac
y’
s e
le
ct
ro
ni
c 
su
rv
ei
lla
nc
e 
re
co
rd
s o
n 
th
e 
us
e 
of
 
an
tim
ic
ro
bi
al
s
R 
+ 
Q
U
A
N
 
II
I
1)
 P
oi
nt
 p
re
va
le
nc
e 
su
rv
ey
 o
n 
O
L 
A
M
T 
in
 a
ll 
w
ar
ds
 o
f t
he
 h
os
pi
ta
l
2)
 E
le
ct
ro
ni
c 
su
rv
ei
lla
nc
e 
re
co
rd
s o
n 
20
 m
os
t 
us
ed
 a
nt
im
ic
ro
bi
al
s i
n 
N
IC
U
 
3)
 A
na
ly
sis
 o
f p
at
ie
nt
 re
co
rd
s o
f N
IC
U
 
pa
tie
nt
s w
ith
 b
lo
od
 c
ul
tu
re
 p
os
iti
ve
 in
fe
ct
io
ns
 
an
d 
A
M
T 
fo
r t
he
 in
fe
ct
io
ns
 
1)
 2
01
4 
(tw
o 
da
ys
 in
 sp
rin
g)
2)
 2
00
9–
20
14
3)
 2
00
5–
20
14
1)
 N
=9
9
2)
 R
E
3)
 N
=2
82
1)
 P
at
ie
nt
 re
co
rd
s a
t t
he
 m
ed
ic
al
 w
ar
ds
 a
t 
th
e 
tim
e 
of
 c
ol
le
ct
io
n
2)
 E
le
ct
ro
ni
c 
pa
tie
nt
 re
co
rd
s i
n 
M
ira
nd
a 
pr
og
ra
m
3)
 H
os
pi
ta
l i
nf
ec
tio
ns
 d
at
ab
as
e 
an
d 
el
ec
tro
ni
c 
pa
tie
nt
 re
co
rd
s i
n 
M
ira
nd
a 
pr
og
ra
m
 o
n 
us
ed
 a
nt
im
ic
ro
bi
al
s i
n 
N
IC
U
R 
+ 
P 
+ 
Q
U
A
L 
+ 
Q
U
A
N
 
IV
A
na
ly
sis
 o
f a
nt
im
ic
ro
bi
al
 m
ed
ic
at
io
n 
er
ro
rs
 
re
po
rte
d 
in
 p
at
ie
nt
s f
ro
m
 fo
ur
 w
ar
ds
 (G
EN
, 
N
IC
U
, H
EM
-O
N
C 
an
d 
IN
F)
20
09
–2
01
4
N
=1
49
 
H
ai
Pr
o 
– 
el
ec
tro
ni
c 
m
ed
ic
at
io
n 
er
ro
r 
re
po
rti
ng
 sy
ste
m
R 
+ 
Q
U
A
L 
+ 
Q
U
A
N
A
M
T=
an
tim
ic
ro
bi
al
 t
he
ra
py
. O
L=
off
-l
ab
el
. G
EN
=P
ae
di
at
ric
 k
id
ne
y 
an
d 
tr
an
sp
la
nt
at
io
n 
w
ar
d 
N
IC
U
=n
eo
na
ta
l i
nt
en
si
ve
 c
ar
e 
un
it,
 H
EM
-O
N
C
=o
nc
ol
og
y 
an
d 
tr
an
sp
la
nt
at
io
n 
w
ar
d 
an
d 
IN
F=
in
fe
ct
io
us
 d
is
ea
se
s 
an
d 
ob
se
rv
at
io
n 
w
ar
d.
 N
=N
um
be
r 
of
 p
at
ie
nt
s 
in
cl
ud
ed
 t
o 
th
e 
st
ud
y,
 R
E=
R
eg
is
tr
y 
st
ud
y 
w
ith
 n
o 
pa
tie
nt
s 
in
cl
ud
ed
, 
R
=R
et
ro
sp
ec
tiv
e 
st
ud
y,
 P
=P
ro
sp
ec
tiv
e 
st
ud
y,
 Q
U
A
L=
Q
ua
lit
at
iv
e 
an
al
ys
is
, Q
U
A
N
=Q
ua
nt
ita
tiv
e 
an
al
ys
is
.
51
4.2.  STUDY POPULATIONS AND REGISTRY DATA
4.2.1.  PATIENTS (I, III)
Two studies involved patients (Table 8). Both studies had patients with blood culture 
positive infections. In Study I, the patients were 0–17 years old and from all wards 
in the hospital. In Study III, two patient cohorts were used. The first cohort had 
patients 0–17 years old from all hospital wards, and the second cohort included 
only premature neonates.
4.2.1.1.  Antimicrobial therapy for children with blood culture positive infections (I)
The Hospital for Children and Adolescents, Helsinki University Central Hospital, 
Finland, is a tertiary-care paediatric centre with 130 beds and approximately 
100 annual blood culture positive BSIs. The most common blood isolates have 
been coagulase negative staphylococci (CONS) covering approximately 50% of all 
isolates. In order to obtain a more heterologous material for this analysis, five 
different groups of blood culture positive infections caused by different pathogens 
(Staphylococcus aureus, Staphylococcus epidermidis, streptococci, Gram negative 
rods and polymicrobial infections) were collected. This was done due to the natural 
occurrence of the causative bacteria in BSIs. At the Children’s Hospital, infections 
caused by Gram positive bacteria are more common than infections caused by 
Gram negative bacteria (Figure 2). Since Gram positive bacteria are the causative 
agents in most cases, collecting Gram negative bacteria was also seen as important 
since they are generally more virulent and more complex to treat. The aim was to 
gather approximately 30 patients/group.
Data of the patients with blood culture positive infection was received from 
hospital infections registry database (Table 9.). Data from patients who suffered from 
infections caused by S. aureus, S. epidermidis, streptococci, Gram negative rods and 
polymicrobial infections were collected retrospectively in order of appearance from 
June 2012 backwards until year 2005. Due to the fact that S. epidermidis infections 
may often be caused by contaminants from the skin, patients with this bacterium 
were screened carefully in this study in order to include only those patients who 
had a blood culture positive infection (in most cases, fever and elevated leukocytes 
were present). Infections caused by fungi and anaerobes were uncommon and were 
therefore not analysed.
The following characteristics were recorded for each patient (if available): age, 
gender, duration of hospitalization, diagnosis and co-morbidities, weight, height, 
drug allergies, the use of antimicrobials 7 days prior to the diagnosis, the date of 
blood sample taken, the date of final blood culture results (i.e., when pathogen was 
52
4. Materials and methods
identified and the antibiogramme was given), leukocytes (neutrophils), empirically 
used antimicrobials, duration of empirical AMT days prior to receiving blood culture 
results and the antimicrobials selected after the blood culture result. Patients with 
no pathogens present in the final blood culture results were excluded from the 
study. The route of administration of antimicrobials was not recorded due to the 
fact that this study focuses on the choice of antimicrobial(s) and the appropriateness 
of AMT after final blood cultures have been received. For all antimicrobials used, 
the following were recorded: duration of AMT in days in total, antimicrobial 
used, dosing, formulation and duration of therapy individual antimicrobial. The 
surveillance period was from 7 days prior to receiving the positive blood culture 
to 30 days after the AMT for a healthcare-associated BSI was stopped or to the 
death of a patient.
4.2.1.2.  Off-label use of antimicrobials in the Children’s Hospital and in premature 
neonates (III)
This patient data consisted of patients of all ages from all hospital wards in order 
to investigate the prevalence of OL use in different patient groups, younger versus 
older children and patients with different co-morbidities (Table 9.). Thereafter, a 
prevalence study was conducted by selecting two random days during which the use 
of antimicrobials among all hospitalized patients was recorded in order to identify 
the prevalence of OL use. After the identification of the patients, the drugs used 
were recorded from electronic patient records. The patient data were collected by 
nurses and pharmacists on duty at the time and comprised patient’s age, ward and 
antimicrobials used (active substance, dose and route of administration).
After the first study was conducted, a second study population was examined, 
consisting of premature neonates with a birth weight of less than 2000g who had 
blood culture positive infections (Table 9.). Blood culture positive infections were 
chosen because these infants were treated with antimicrobials. The list of eligible 
patients was retrieved from the hospital infections database. Patients were divided 
into four different weight categories based on Hack et al. [118]. All antimicrobials 
administered to these neonates during the first month (30 days) of life from 
2005 to 2014 were recorded. Patients with insufficient data, e.g., cases where the 
antimicrobials used were not included in the patient records, were excluded. The 
data on the used antimicrobials were obtained from electronic patient records and 
included the individual drugs used and the duration of the AMT. It did not include, 
for example, the dosing of these drugs. Information regarding dosing, dosage form or 
route of administration was not available from the electronic records since electronic 
prescribing started at The Children’s Hospital only in 2014. Thus, complete data on 
drugs, including dosing, have been available electronically from only 2014 onwards. 
53
4.2.2.  REGISTRY DATA (II, III, IV)
Three studies involved the use of registry data on either the consumption of 
antimicrobials or occurrence of antimicrobial medication errors at the hospital.
4.2.2.1.  Consumption of antimicrobials in Defined Daily Doses (II)
This retrospective study investigated the consumption of antimicrobials in Defined 
Daily Doses, DDD according to the Anatomical Therapeutical Chemical (ATC)/DDD 
index defined by the WHO [118].
The antimicrobials included in this study were the following (according to 
Anatomical Therapeutical Chemical (ATC)/DDD index defined by WHO, 2010):
J Anti-infectives for systemic use: 
J01 Antibacterials: J01A Tetracyclines, J01B Amphenicols, J01C Beta-lactam 
antibacterials, penicillins, J01D Other Beta-lactam antibacterials, J01E Sulfonamides 
and trimethoprim, J01F Macrolides, Lincosamides and streptogramins, J01G 
Aminoglycoside antibacterials, J01M Quinolone antibacterials, J01R Combinations 
of antibacterials, J01X Other antibacterials.
J02 Antifungals: J02AA Antibiotics, J02AC triazoles, J02AX Other systemic 
antifungals.
J05 Antivirals: J05AB Nucleosides and nucleotides excluding reverse transcriptase 
inhibitors, J05AD Phosphonic acid derivatives, J05AE Protease inhibitors, J05AF 
Nucleoside and nucleotide reverse transcriptase inhibitors, J05AG Non-nucleoside 
reverse transcriptase inhibitors, J05AH Neuraminidase inhibitors, J05AR Antivirals 
for treatment of HIV infections.
The data on the consumption of antimicrobials were collected from 2003 to 
2013 from electronic surveillance records provided by Helsinki University Central 
Hospital (HUCH) pharmacy. Analysis was quantitative. The data regarding the 
days of hospital care were collected from HUCH electronic records. During 2003 
and 2013, the days of hospital care (HD) varied annually between 30,226–39,930. 
Electronic surveillance records did not allow us to differentiate enteral and 
parenteral use from antimicrobials that are available in both parenteral and enteral 
formulations. Therefore, enteral consumption was included in the study from drugs 
that have both enteral and parenteral formulations, such as trimethoprim, penicillins 
such as cloxacillin, fluoroquinolones, metronidazole, azoles and antivirals. Drugs 
with the same ATC code, such as amphotericin deoxycholate and liposomal 
amphotericin could not be separated and the total DDD describes them both.
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4.2.2.2.  Off-label use of antimicrobials in NICU (III)
At the same time as patient data collection was conducted for Study III (Table 9.), 
data were collected on the 20 most commonly used antimicrobials in the NICU 
from 2009 to 2014. The data regarding antimicrobial consumption in NICU was 
available from 2009 onwards. The data were obtained from the hospital’s electronic 
registry of antimicrobial consumption in DDDs. 
4.2.2.3.  Medication errors and HaiPro reporting system (IV)
Medication safety in the Children’s Hospital was investigated by using registry data 
on reported medication errors. HaiPro is a web-based tool for anonymous and 
voluntary reporting of patient safety incidents [120]. HaiPro is used in Finland in 
over 200 social service and healthcare organizations of various sizes, from small 
healthcare centres to entire hospital districts. 
When a medication error occurs, healthcare professionals are advised to report 
the errors. The following factors are obliged to be reported when using the HaiPro 
system: reporter’s unit, incident time and date, reporter’s occupation, incident 
nature (near miss/adverse event) and incident description. In addition, there are 
also open questions about why the reporter thinks the error occurred and what 
sort of measures can be introduced in the future to prevent these types of errors. 
In the Children’s Hospital, the HaiPro reporting system has been in use from 
2007 or 2009, depending on the ward. Initially, errors were reported via paper forms. 
In 2009, a digital HaiPro database was deployed in the hospital. From the launch 
of the reporting system to 2014, more than 2000 medication errors were reported. 
Errors were analysed from the following departments: general paediatrics and 
transplantation ward (GEN), neonatal intensive care unit (NICU), oncology and 
haematology ward (HEM-ONC) and infectious diseases ward (INF). 
4.3.  METHODS
4.3.1.  EVALUATING THE APPROPRIATENESS OF ANTIMICROBIAL THERAPY IN 
CHILDREN WITH BLOOD CULTURE POSITIVE INFECTIONS (I)
In this study, the appropriateness of targeted antimicrobial therapy was evaluated. 
The main focus of the study was the use of antimicrobials during the 72-hour 
window of time immediately after the final data on a positive blood culture was 
provided by the microbiology laboratory. Thus, the medical doctor(s) in charge 
was allowed 72 hours to respond to the microbiological data. If necessary changes 
in AMT were not made during this given time period (of 72 hours), the targeted 
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AMT was considered inappropriate. The quality of the targeted AMT given to each 
patient was evaluated retrospectively by an expert panel of three medical doctors: 
one clinical microbiologist (MV) and two infectious diseases consultants (V-JA and 
HS). The decision of whether the AMT of a particular patient was inappropriate or 
not, was consensus-based. This study did not evaluate the initial empiric therapy. 
When evaluating the quality of therapy for HCA BSI, the following demographic 
characteristics were taken into account by the panel: age, co-morbidities, causative 
pathogen/pathogens and the level of granulocytes. A leukocyte count of < 1.0 x 
109/L) was considered as neutropenia. In general, antimicrobials having a broader 
spectrum were allowed in the treatment of patients with neutropenia (< 1.0 x 109/L) 
compared with patients with normal white blood cell counts. 
Inappropriate targeted AMT was divided in two categories: 1) the isolated 
pathogen was resistant to the selected antimicrobial(s), or 2) the isolated pathogen 
was either treated with an antibiotic with suboptimal efficacy or the pathogen was 
treated with overly broad-spectrum agents. Each patient was categorized into one 
category according to only the clinical significance of the inappropriateness of AMT. 
If the patient received both type 1 and type 2 inappropriate AMT, the patient was 
categorized into both of these categories. Analysis used in the study was both 
quantitative and qualitative. 
Blood cultures were taken whenever an invasive infection was suspected. 
Blood culture samples were incubated in the BacT/Alert automated blood culture 
system (Biomérieux, France). Antibiotic susceptibility testing was performed using 
the disk-plate diffusion method and interpreted according to CLSI breakpoints 
(2005–2010) and EUCAST breakpoints (2011–2012). Data from the pro-forma 
were routinely entered into Microsoft Access (Microsoft Corporation, Redmond, 
WA; www.microsoft.com) and fully anonymised prior to analysis with Stata v.11.0 
TM (Statacorp, College Station, Tx, US; www.stata.com). Patients with a minimum 
of two different pathogens detected in one blood culture sample were assigned to 
the polymicrobial pathogen group.
Hospital-acquired bacteremia was determined according to the classic CDC 
criteria, where laboratory-confirmed bloodstream infection is LCBI. LCBI is 
equivalent to this study’s determination of HCA BSI. 
The study was reviewed and approved by the local paediatric Ethical Committee.
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4.3.2.  MEASURING THE CONSUMPTION OF ANTIMICROBIALS (II)
In Study II, the change (in percent) in the consumption of antibacterials was 
calculated by using linear function over the consumption of antimicrobials from 
2003 to 2013. This approach was in use when the drug had been used throughout 
the entire surveillance period (i.e., 2003–2013). If the consumption of a drug started 
later than 2003, the change in percentage was calculated by the year the drug use 
was initiated, for example, the use of micafungin was initiated in 2010. Electronic 
surveillance records did not allow the use of the individual ages of the children 
treated during the study period. Similarly, data on individual weights were not 
available. Hence, this study did not investigate the use of antimicrobials in children 
by using age-specific bands. 
This retrospective registry study did not require the approval of the local ethical 
committee. 
4.3.3.  INVESTIGATING OFF-LABEL USE OF ANTIMICROBIALS IN FULL-TERM AND 
PRETERM NEONATES (III)
In Study III, labelled drug use was determined according to the product label [121]. 
SmPC is a legal document approved as a part of the marketing authorization for 
each drug. The SmPC is the basis of information for the healthcare professional 
on how to use the drug. Its information is updated throughout the life-cycle of 
the product as new data emerge [122]. Off-label (OL) drug use was determined as 
follows: the prescribed antimicrobials were determined as either labelled or OL use 
in relation to weight only. Age was not taken into account. The cumulative use of 
various antimicrobials was calculated in DDDs in NICU from 2009 to 2014. DDDs 
were based on adult DDDs. There are no DDDs defined for paediatric patients [123]. 
The retrospective registry study did not require an approval of the local ethical 
committee, otherwise study III was reviewed and approved by the local paediatric 
Ethical Committee.
4.3.4.  ANALYSING ANTIMICROBIAL ERRORS (IV)
The occurrence of antimicrobial (antibacterial, antifungal and antiviral) medication 
errors in June 2009 to December 2014 was analysed retrospectively in all wards 
except the NICU, where the data were available from the year 2010. A medication 
error was defined as following: an unintended failure in the drug treatment process 
that leads to, or has the potential to lead to, harm to the patient [76].
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Complete HaiPro data was received from the GEN, HEM-ONC and INF 
departments. With NICU, partial data were collected retrospectively from the HaiPro 
registry by nurses working in NICU. 
Statistical analysis was qualitative and quantitative.
The study was reviewed and approved by the local paediatric Ethical Committee. 
Patients and caregivers cannot be identified from the HaiPro reports.
4.4.  STATISTICAL ANALYSIS 
In majority of the studies, qualitative and quantitative analyses were applied and 
the studies were descriptive in nature (Table 9.). For these studies, basic percentage 
calculations and ratios were utilized. In the OL antimicrobial use study (III), 
statistical analysis was conducted by using a logistic regression model fitted for 
OL usage with categorical birth weight as the predictive explanatory variable using 
R software [124]. Odds ratio, confidence interval (CI 95%) and p-value were also 
calculated. 
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5. RESULTS
5.1.  EVALUATION OF ANTIMICROBIAL THERAPY OF 
BLOOD CULTURE POSITIVE HEALTHCARE-ASSOCIATED 
INFECTIONS IN CHILDREN (I)
5.1.1.  PATIENT PROFILES AND EPIDEMIOLOGY 
In total, 149 patients with blood culture positive infections with different types of 
causative pathogens were included (Table 10.). From these patients, 72/149 (48%) 
infants were either term or preterm neonates (≤ 28 days of age), the age of 24/149 
(16%) children varied between 29 days and 1 year, the age of 39/149 (26%) infants 
was between 1 and 12 years, and 14/149 (9%) paediatric patients were between the 
ages of 12 and 17 years. 
Table 10. Demographic data of the selected patients with HCA-bloodstream infections (n=149). 
Pathogen 
group/ co-
morbidities
Patients/
pathogen 
group
Full-term 
neonates
(< 28 days) 
Premature 
neonates
(born < 37 
weeks old)
Patients with 
malignancies
*Surgical 
patients 
^Other co-
morbidities
Patients, 
n (%)
Patients, 
n (%)
Patients, 
n (%)
Patients, 
n (%)
Patients, 
n (%)
Patients, 
n (%)
Staphylococcus 
aureus
25 (17) 3 (12) 6 (24) 5 (20) 8 (32) 3 (12)
Staphylococcus 
epidermidis
33 (22) 1 (3) 8 (24) 12 (36) 10 (30) 2 (6)
Streptococcal 
species
30 (20) 18 (60) 4 (13) 5 (17) - 3 (10)
Gram negative 
bacteria
38 (26) 8 (21) 14 (37) 3 (8) 9 (24) 4 (11)
Polymicrobial 
infections
23 (15) 1 (4) 9 (40) 12 (52) 1 (4) -
Total 149 (100) 31 (21) 41 (28) 37 (25) 28 (19) 12 (8)
*Surgical patients were patients who had undergone surgery during the same hospital admission 
as having BSI. ^Other co-morbidities were defined as patients with co-morbidities that could not 
be classified to any of the given categories.
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The organisms of the streptococcal cohort were the following: Streptococcus 
agalactiae (GBS), (18/30, 60%), Streptococcus viridans (7/30, 23%), Streptococcus 
pyogenes (3/30, 10%), Streptococcus pneumoniae (1/30, 3%) and Streptococcus 
salivarus (1/30, 3%). All of the children infected by GBS were neonates. The 
staphylococcal cohorts consisted of patients infected either with Staphylococcus 
aureus (n=25) or Staphylococcus epidermidis (n=33). S. aureus was the most 
common pathogen isolated from surgical patients (8/25, 32%), and S. epidermidis 
was most frequently found in patients with malignancies (12/33, 36%). No MRSA 
infections were recorded.
The Gram-negative cohort consisted of the following: Escherichia coli (19/38, 
50%) followed by Klebsiella pneumoniae and Klebsiella oxytoca (6/38, 16%), 
Pseudomonas aeruginosa (4/38, 11%), Enterobacter cloacae (3/38, 8%), Serratia 
marcescens (2/38, 5%), Citrobacter (n=1), Stenotrophomonas maltophilia (n=1), 
Sphingomonas paucimobilis (n=1) and an unidentified Enterobacteriaceae strain 
(n=1). Two patients suffered from bacteremias that were caused by an ESBL strain 
of E. coli. 
The causative microbes of the polymicrobial group were the following: Gram+ 
Gram+ (9/23, 39%), Gram+ Gram- (9/23, 39%) and Gram- Gram- (5/23, 22%). 
In the case of two polymicrobial infections, three different pathogens were isolated 
simultaneously from the blood culture.
5.1.2.  ADJUSTING THE EMPIRICAL USE OF ANTIMICROBIALS 
The initial empirical antimicrobial therapy of 114 patients (77%) was changed during 
the study period within 3 days (72 hours) after receiving the final blood culture 
results. Empirical AMT was changed in 87% of cases in the polymicrobial infection 
group (20/23). In the other groups of pathogens, the treatments were changed as 
follows: Staphylococcus aureus 20/25 (80%), Staphylococcus epidermidis 26/33 
(79%), Gram negative bacteria 27/38 (71%) and streptococci 21/30 (70%). 
5.1.3.  INAPPROPRIATE USE OF TARGETED ANTIMICROBIALS 
AMT was considered totally inappropriate in three cases because the pathogen was 
resistant to all prescribed antimicrobials (Table 11.). In one case, an infection caused 
by oxacillin resistant S. epidermidis (MRSE) was treated with cloxacillin, and in 
another case MRSE infection was treated with cefuroxime and fluoroquinolone to 
which the strain was also resistant. One child received cefuroxime monotherapy 
for an infection caused by Pseudomonas sp.
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Table 11. Patients (n=3) who were prescribed entirely inappropriate therapy* due to resistance of the 
pathogen. Antimicrobial therapy (AMT) given 0–72 hours after identification of the pathogen and testing 
its antimicrobial sensitivity.
Age Co-morbidities Isolate Resistant to AMT given
3 months left ventricular 
hypoplasia
S.epidermidis oxacillin cloxacillin*
7 months biliary atresia S. epidermidis clindamycin 
oxacillin 
levofloxacin
ceftriaxone* 
ciprofloxacin
4 years transposition of 
great arteries
Pseudomonas sp. cefuroxime cefuroxime*
Ten patients received at least one antibiotic agent to which the pathogen was resistant 
(Table 12.). Five children with MRSE infections were treated with inefficient beta-
lactams. Two patients with infections caused by Klebsiella received vancomycin. 
One child with an ampicillin-resistant Citrobacter freundii infection was treated 
with ampicillin. One child with a cefuroxime-resistant Stenotrophomonas infection 
was treated with cefuroxime, and another child with E. coli resistant to ciprofloxacin 
and penicillin was treated with ciprofloxacin and penicillin G. 
Out of all 149 patients in the cohort, 13 (9%) received inappropriate AMT due 
to therapy that was considered to be of suboptimal efficacy against the pathogen. 
The most common cause for suboptimal use of AMT was the use of vancomycin in 
treating infections caused by methicillin-sensitive S.aureus (MSSA) (n=6) and in 
treating one patient with a methicillin-sensitive St. epidermidis (MSSE) infection. 
One MSSA infection was treated with penicillin G (and ceftriaxone) and one MSSA 
with both intravenous cefuroxime and oral cephalexin. One child with a penicillin-
sensitive Streptococcus viridans was treated with meropenem, and another with 
an Enterobacter cloacae infection received cefuroxime monotherapy. Finally, one 
patient with a mixed infection caused by E. cloacae and Enterococcus faecalis 
received meropenem—an agent with suboptimal activity against the enterococcus. 
Another mixed infection caused by Enterococcus faecalis and an oxacillin-resistant 
Staphylococcus sp was treated with vancomycin, ampicillin and meropenem. Here, 
meropenem use was considered unnecessary.
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Table 12. Patients (n=10) who were prescribed inappropriate therapy* due to resistance of the pathogen 
to one of the chosen antimicrobials. Antimicrobial therapy (AMT) given 0–72 hours after identification of 
the pathogen and testing its antimicrobial sensitivity.
Isolate N Pathogen resistant to AMT given
S. epidermidis 1 oxacillin cefuroxime*  
netilmycin
S. epidermidis 1 oxacillin cefuroxime* 
clindamycin
S. epidermidis 1 oxacillin cefuroxime* 
metronidazole
S. epidermidis 1 oxacillin vancomycin 
meropenem*
S. epidermidis 1 oxacillin teicoplanin 
meropenem*
Citrobacter sp. 1 ampicillin penicillin G* 
netilmycin
Stenotrophomonas 
maltophilia
1 cefuroxime cefuroxime* 
trimethoprim-
sulfamethoxazole
E. coli 1 cefuroxime  
(ESBL)  
ciprofloxacin
penicillin G*
meropemen
ciprofloxacin*
Klebsiella pneumoniae 1 vancomycin vancomycin*
cefuroxime
Klebsiella pneumoniae 1 vancomycin vancomycin*
metronidazole
cefuroxime
Inappropriate AMT was found to be most common in the treatment of BSIs caused 
by Staphylococcus aureus (8/25, 32%) (Figure 5.). In contrast, inappropriate AMT 
was uncommon in infections caused by streptococcal species: only one patient, with 
ampicillin sensitive Streptococcus viridans, received inappropriate meropenem 
(1/30, 3%). Lack of de-escalation was a concern in the case of two patients: S.viridans 
infection was continued on meropenem treatment after the blood culture result was 
available. In addition, a polymicrobial infection (caused by Enterococcus faecalis 
and Staphylococcal species) received meropenem.
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Figure 5. 26 patients (26/149, 17%) received inappropriate AMT 0–72 hours after receiving blood culture 
results. 
5.1.4.  OUTCOME OF ANTIMICROBIAL THERAPY
Mortality rate among the study patients was low. From the cohort of 149 patients, 
seven patients died (5%). Out of these seven patients, infection was the main cause of 
death in two cases only. Neither of these patients, however, died due to inappropriate 
AMT. The causes of death in these two cases were 1) duodenal atresia + sepsis and 
2) neuroblastoma + sepsis.
5.2.  ANTIMICROBIAL CONSUMPTION IN A TERTIARY 
CHILDREN’S HOSPITAL IN FINLAND (2003–2013) (II)
5.2.1.  ALL ANTIMICROBIALS 
The overall consumption of systemic antimicrobials (according to ATC classes and 
in DDDs) during the study period 2003–2013 was relatively stable (18,843–23,057 
DDD) (Figure 6.). The days of hospital care (HD) varied annually between 30,226–
39,930. The mean annual use of the antimicrobials was 20,800 DDDs, and the 
mean consumption per hospital days was 0.55 DDD/HD. 
When the consumption of antimicrobials was calculated per patient days, the 
most frequently used pharmaceuticals were antibacterials (mean annual use 15,100 
DDD and 0.40 DDD/HD) covering approximately 72% of all use. The second most 
commonly used group of drugs were antifungals at 18% of all use (3,700 DDD and 
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0.10 DDD/HD). Antivirals represented 10% (1,900 DDD and 0.05 DDD/HD) of 
all antimicrobial consumption.
Overall consumption of systemic antimicrobials in DDDs according to ATC 
classes divided by the days of hospital care (HD)/year in the Children’s Hospital 
from 2003 to 2013 is shown in Figure 6. 
Figure 6. Overall consumption of antimicrobials in the Children’s Hospital from 2003–2013 according to 
ATC classification and in defined daily doses (DDDs) divided by the annual days of hospital care (HD).
5.2.2.  ANTIBACTERIALS 
From 2003 to 2013, the most frequently used group of antibacterials were beta-
lactams, other than penicillins (J01D), including cephalosporins and carbapenems 
(annual consumption between 0.20–0.22 DDD/HD). The second most commonly 
used group of antibacterials were penicillins J01C (annual consumption between 
0.070–0.105 DDD/HD). 
Overall, when the early use (2003–2006) of penicillins, cephalosporines and 
carbapenems was compared to later use (2006–2013), a clear increase of 28%, 
46% and 110% was recorded (Figure 7.). However, the use of aminoglycosides and 
vancomycin decreased during the same time periods by 61% and 41%, respectively. 
A closer look at the drugs used against Pseudomonas infections revealed that the 
consumption of the antibacterials, such as carbapenems, piperacillin tazobactam 
and ceftazidime, increased constantly from 2003 to 2013 by 110%, 500% and 47%, 
respectively (Figure 8.). During the study period, the total number of invasive 
Pseudomonas infections, however, did not increase. Also, it was not possible to 
see any major differences in the drug resistance pattern of the isolates.
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5.2.3.  BETA-LACTAM ANTIBACTERIALS (PENICILLINS, CEPHALOSPORINS AND 
CARBAPENEMS)
The use of different beta-lactams is shown in Figure 7. Cefuroxime was the single 
most frequently used antibacterial agent, and its use grew steadily from 2003 to 
2013. A clear change in consumption of ampicillin was seen 2006–2007 when 
compared to previous years. At the same time, the use of penicillin G was increased. 
Overall, from 2003 to 2013, the use of ampicillin decreased by 94% and the use of 
penicillin G increased by 100%. This shift from ampicillin to penicillin G took place 
due to changes in therapy recommendations given in 2006. 
5.2.4.  NON BETA-LACTAM ANTIBACTERIALS
Overall, the use of non beta-lactams did not change significantly from 2003 to 2013. 
The consumption of both aminoglycosides and vancomycin decreased by 61% and 
41%, respectively, whereas the use of fluoroquinolones remained mainly the same. 
Figure 7. The use of beta-lactam antibacterials in the Children’s Hospital from 2003–2013 according to 
ATC classification, penicillins (J01C), cephalosporins (J01DC, J01DD) and carbapenems (J01DH) in defined 
daily doses (DDDs) divided by the days of hospital care (HD)/year.
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5.2.5.  ANTI-PSEUDOMONAS ANTIBACTERIALS 
In general, Pseudomonas species have been rare causes of invasive infections at the 
Children’s Hospital. Nevertheless, the use of anti-pseudomonas drugs has grown. 
From 2003 to 2013, the use of aminoglycosides has decreased by 61%, whereas the 
use of piperacillin tazobactam, ceftazidime and carbapenems increased by 500%, 
47% and 110% (Figure 8.), respectively. 
The resistance of P.aeruginosa towards different antibacterials has somewhat 
increased over time. The antibiotic sensitivity of 435 Pseudomonas aeruginosa 
strains isolated from the blood or superficial samples taken from 2003 to 2013 were 
analysed (Figure 9.). Some year-over-year variation in resistance was seen. Overall, 
the resistance towards different antibacterials seemed to increase. For example, 
resistance towards piperacillin tazobactam reached its peak in 2011 when almost 
40% of the isolates were resistant to the drug. Resistance towards meropenem and 
ciprofloxacin has likewise grown rapidly; in 2012, approximately 50% of the isolates 
were resistant to these drugs.
Figure 8. The use of anti-Pseudomonas antibiotics in defined daily doses (DDDs) according to ATC classes 
divided by the days of hospital care/year in the Children’s Hospital from 2003–2013.
66
5. Results
A) The resistance % of P.aeruginosa isolates towards beta-lactam antibacterials.
B) The resistance % of P.aeruginosa isolates towards aminoglycosides and ciprofloxacin.
Figure 9. Pseudomonas aeruginosa, blood and pus isolates 2003–2013 in the Children’s Hospital. 
One isolate/patient (the most resistant one). The number of isolates/year varied from 29–46, total 
N of isolates was 435. 
67
5.2.6.  ANTIFUNGALS
The overall consumption of all antifungals was somewhat decreased during the study 
period. From 2003 to 2013, the use of amphotericin and fluconazole decreased by 
39% and 23%. On the contrary, during the same period, the use of voriconazole, 
posaconazole, caspofungin and micafungin increased by 34%, 295%, 134% and 
67% (2010–2013), respectively (Figure 10.).
Figure 10. The use of antifungals in defined daily doses (DDDs) according to ATC classes divided by the 
days of hospital care (HD)/year in the Children’s Hospital from 2003–2013. 
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5.2.7.  ANTIVIRALS 
The consumption of frequently used antivirals, such as valganciclovir, aciclovir 
and valaciclovir increased by 29%, 28% and 153%, whereas the use of ganciclovir 
decreased by 68% from 2003 to 2013.
5.3.  OFF-LABEL USE OF ANTIMICROBIALS IN NEONATES IN A 
TERTIARY CHILDREN’S HOSPITAL (III)
5.3.1.  OFF-LABEL USE IN THE HOSPITAL 
Surprisingly, out of 99 patients included, only 6% (6/99) received off-label 
antimicrobials according to age (Tables 13. and 14.). Due to these results, more 
careful focus was given to premature neonates and NICU. 
5.3.2.  MOST FREQUENTLY USED ANTIMICROBIALS IN NICU 
Measured in DDDs, meropenem was the most frequently used OL antimicrobial with 
235 DDDs, while the total consumption of antimicrobials was 3547 DDDs (Figure 
11.). Meropenem was followed by levofloxacin, rifampicin, piperacillin tazobactam, 
clindamycin, trimethoprim and ciprofloxacin, whereas the most commonly used 
labelled antimicrobials, measured in DDDs, were penicillin G (benzylpenicillin) 
with 1391 DDDs, vancomycin, metronidazole and netilmicin. 
The most commonly used OL antifungals were amphotericin (43 DDDs) and 
caspofungin (42 DDDs), whereas fluconazole (581 DDDs) was used according to 
the product label. The antiviral most commonly used OL was valganciclovir (36 
DDDs), whereas acyclovir (54 DDDs), ganciclovir (48 DDDs) and zidovudine (22 
DDDs) were used according to the label in neonates.
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#The number of DDDs for the use of Penicillin G is 1391.
Figure 11. The 20 most frequently used antimicrobials in NICU measured in Defined Daily Doses (DDDs) 
between 2009 and 2014. Prevalence of off-label (OL)* use is shown with black bars. Prevalence of label 
use is shown with grey bars. 
5.3.3.  ANTIMICROBIAL THERAPY OF BLOOD CULTURE POSITIVE INFECTIONS IN 
PREMATURE NEONATES WITH BIRTH WEIGHT OF 400–2000G 
There were 282 premature neonates with blood culture positive infections included. 
The number of eligible neonates varied from year to year between 22 and 37. Almost 
one-fifth of the patients (18%, 51/282) received at least one OL antimicrobial (Table 
15.). 
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Table 15. Neonates weighing 400–2000g (N=282), and number of times antimicrobial was used off-label 
(OL) in 2005–2014 for blood culture positive infections.
Weight group
Weight 400–750g* 751–1000g 1001–1500g 1501–2000g 400–2000g
Patients with OL use / 
weight group, n
N=14/49  
(29%)
N=16/64  
(25%)
N=18/123  
(15%)
N=3/46  
(7%)
N=51/282  
(18%)
Times 
antimicrobial 
used/weight 
group, n
Meropenem 13 14 16 2 45/282 (16%) 
Rifampicin 3 2 4 - 9/282 (3%)
Ciprofloxacin 
and Levofloxacin
4 1 1 - 6/282 (2%)
Linezolide 1 - - - 1/282 (<1%)
Clindamycin - 1 - - 1/282 (<1%)
Erythromycin - 1 - - 1/282 (<1%)
Piperacillin 
tazobactam - - - 1 1/282 (<1%)
Caspofungin - - 1 - 1/282 (<1%)
On average, each neonate was given 1.3 antimicrobials OL. Meropenem was the 
most commonly used OL antibiotic, as 16% (45/282) of the neonates with blood-
culture positive infections received this carbapenem. Other antimicrobials used 
without market authorization were rifampicin (3%, 9/282) and ciprofloxacin and 
levofloxacin (2%, 6/282). OL antimicrobial use varied according to weight group. 
An increase in birth weight was found to statistically significantly decrease the 
probability of OL usage (odds ratio=0.85 for 100g increase in birth weight, p-value < 
0.001). The odds for OL use were higher the smaller the birth weight was (Figure 12.). 
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A)             B)
 
Figure 12. Neonates weighing from 400–2000g (N=282) with blood culture positive infections and 
the prevalence of off-label (OL) antimicrobial drug use. A) Number of patients with labelled/OL use of 
antimicrobials. B) Percent of patients with one or more OL antimicrobial used.
5.4.  MEDICATION ERRORS RELATED TO ANTIMICROBIAL 
THERAPY IN A TERTIARY CHILDREN’S HOSPITAL (IV) 
5.4.1. REPORTED ANTIMICROBIAL MEDICATION ERRORS 
There were a total of 149 patients with 157 antimicrobial errors (1.1 errors/patient) 
between 2009 and 2014. The number of reported errors varied between departments 
with the highest number occurring in the INF ward and the lowest in the GEN ward 
(Table 16). These figures correlated with the total number of patients treated in 
these wards. Of the reported errors, 84% reached the patient (125/149). During the 
study period, there were on average 0.0017 errors reported annually/days of care. 
The annual number of reports increased over time. Thus, there were 23 patients at 
the beginning of the study period in 2010 (first full year) and 34 patients in 2014 
who experienced antimicrobial medication error(s).
73
Most of the reported errors were related to administration (99/149, 66%), 
followed by prescription (12/149, 8%), transcription (8/149, 5%), preparation of 
the drug (6/149, 4%) and other (2/149, 1%). In 15% of the cases, the error type was 
not reported (22/149). Under administration errors, omission was most common 
error subtype (37/149, 25%), followed by a wrong dose prescribed, or prepared or 
given (36/149, 24%) and a wrong drug prescribed, or prepared or given (10/149, 7%).
Errors occurred more often with IV (intravenous) administered antimicrobials 
(116/149, 78%) when compared to PO (oral) administered antimicrobials (33/149, 
22%). 
Most errors took place with beta-lactams (Figure 13.). Drugs that were frequently 
involved in the errors were parenteral cefuroxime (15/157, 10%), penicillin G 
(15/157, 10%), parenteral vancomycin (13/157, 8%), netilmicin (12/157, 8%) and oral 
amoxicillin (12/157, 8%). Fluconazole was the most commonly reported antifungal 
involved in all antimicrobial errors (5/157, 7%). Aciclovir/valganciclovir were the 
most commonly reported antivirals (6/157, 4%). The antimicrobial-related and 
system-based antimicrobial medication errors that reached the patient can be seen 
in Table 17.
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Figure 13. Antimicrobials involved in reported antimicrobial medication errors (N=157). 
No fatal errors occurred. There were only two errors that were reported as clinically 
significant errors (2/149, 1%). The first incidence involved an interval that was 
too short for administering teicoplanin (Table 17) The interval was only 7 hours, 
whereas the recommended interval (after the therapeutic concentration is reached) 
is 24 hours. After identifying the error, the infusion was discontinued and safety 
tests were ordered. An exceptionally heavy workload at the NICU was reported as 
a contributing factor. 
The second incident involved a very sick premature neonate who received a 
10-fold overdose of vancomycin because the nurse forgot to dilute the drug. The 
neonate developed muscle spasms that were most probably related to the overdose. 
A sample for drug monitoring was taken, and furosemide was administered. Lack 
of experience in diluting pharmaceuticals was reported as a contributing factor. 
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5.4.2.  ELECTRONICAL PRESCRIPTION PROGRAM CONTRIBUTING TO ERRORS
There was one error where, according to reporters, the computer program used 
was considered as a contributing factor. In this case, penicillin G was accidentally 
prescribed instead of vancomycin. The electronic prescription application used 
always recommends the most frequently used drugs for new patients. At the 
NICU, the most commonly used—and recommended drugs—were penicillin G 
and netilmicin. The patient who was supposed to receive vancomycin received 
penicillin G by mistake. The correct antibiotic was administered 4 hours too late. 
The nurse who reported this error suggested that such an application should be 
deleted from the program. 
A second notable error, related to prescription application, was a case where 
ceftazidime and cloxacillin were prescribed in grams instead of milligrams. The 
prescriber was used to prescribing these drugs in milligrams, but the program 
transferred the milligrams to grams automatically since prescribing was according to 
grams instead of milligrams. Hence, a child was prescribed ceftazidime 800g three 
times daily and cloxacillin 400g four times daily. The error did not reach the patient. 
5.4.3.  CULTURE OF REPORTING MEDICATION ERRORS 
Overall, the reporting activity increased during the study period between June 2009 
and 2014 (Figure 14.). Medication errors were most often reported in the INF ward.
In 87% (130/149) of cases, the report was made by a registered nurse. In 10% 
(15/149) of cases, the reporter was a pharmacist and in 3% (4/149) of cases, a 
medical doctor. 
Full data, including the contributing factors reported as leading to medication 
error according to the reporter, were received from wards GEN, HEM-ONC and 
INF but not from the NICU. Primary contributing factors leading to errors were 
documented in 82% (86/105) of reports. Secondary contributing factors were 
documented in only 63% of the reports (66/105). There were some differences 
when comparing reporting activity between wards: reporting of the contributing 
factor was more common in GEN, 92% (22/24) and HEM-ONC, 27/28 (96%) than 
in INF, 69% (37/53). 
The primary contributing factors for errors reported by the three wards (n 
errors=105) were related to environment, equipment and resources, 26% (27/105); 
way of acting and policy at the ward, 14% (15/105); and communication, 13% 
(14/105). Administration error was the most common error type (85/105, 81%). 
The primary contributing factor for administration error was reported in 78% of 
cases (66/85). 
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* Data from NICU between 2010 and 2014.
Figure 14. Annually (June 2009 – December 2014) reported antimicrobial medication errors/Days of care. 
GEN=Paediatric kidney and transplantation ward NICU=neonatal intensive care unit, HEM-ONC=oncology 
and transplantation ward and INF=infectious diseases and observation ward. 
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6. DISCUSSION
6.1.  ANTIMICROBIAL THERAPY IN BLOOD CULTURE POSITIVE 
INFECTIONS (I)
To our knowledge, Study I was the first study investigating the quality of AMT in 
children with HCA BSIs. This study focused on the vigilance of medical doctors 
in responding to microbiological results and on the appropriateness and quality 
of the targeted antimicrobial therapy. The applied approach of using a selected 
cohort consisting of different causative pathogens did not allow us to calculate the 
total magnitude of inappropriate use of antimicrobials of all blood culture positive 
infections at the Children’s Hospital. It did, however, give us a general picture of 
which pathogens were most often targeted with inappropriate AMT. 
Overall, we discovered that 77% of patients in the cohort had their empirical AMT 
changed after receiving the final blood culture results and 17% of these patients with 
HCA BSIs received inappropriate targeted AMT. The microbiological results were 
frequently either totally (2%) or partly ignored (17%) in the design of the subsequent 
treatment. Similarly, the choice of antimicrobial agents with suboptimal or overly 
broad-spectrum efficacy was not uncommon (9%). Surprisingly, inappropriate use of 
vancomycin in treating MSSA was the most frequent cause of inappropriate use. The 
second most common misuse was treatment of MRSE infections with beta-lactams. 
In all, beta-lactams were the most frequently misused group of antimicrobials. 
Inappropriate AMT was not associated to mortality.
A study by Willemsen et al. speculated that when evaluating incorrect use, 
the following parameters should also be taken into account: dosage, timing, 
administration and duration of AMT, rather than evaluating only the choice of the 
antimicrobial [66]. Due to the retrospective nature of Study I and the fact that we 
evaluated solely the choice of the antibiotics, we may assume that the frequency of 
inappropriate use of AMT was even higher than that reported. This is alarming since 
17% of patients were receiving inappropriate AMT based only on the evaluation of 
the prescribed antimicrobial.
In Study I, vancomycin and carbapenems were the most inappropriately used 
antimicrobials. Two studies reported inappropriate use of vancomycin [61, 67]. Their 
main findings were similar to those of Study I, that one of the most frequently misused 
antimicrobials was vancomycin. The reason for this excessive use of vancomycin 
was not clear. One reason may be that many empiric therapy guidelines included 
vancomycin, but once the data on the pathogen were revealed, de-escalation was 
not executed. Hence, de-escalation of the drug should be conducted more often. 
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6. Discussion
Increased provider awareness of drug-resistant CONS likely also increased the 
overall use of vancomycin. Similar findings have been published by Levy et al. [72]. 
A study by Di Pentima et al. investigated the impact of an ASP on vancomycin use 
in a paediatric teaching hospital and likewise identified excessive use of the drug 
[125]. The ASP reduced vancomycin utilization, prescribing errors and improved 
the quality of care and safety of paediatric patients.
Inappropriate vancomycin therapy in children can also occur when therapeutic 
drug monitoring (TDM) is not conducted or conducted incorrectly [125–130]. TDM 
is needed when using vancomycin due to the drug’s nephrotoxicity [130]. Conducting 
TDM is particularly important when treating premature neonates and children with 
renal insufficiency or anomalies [132]. The problematic sides of conducting TDM 
include wrong timing of sampling (trough and peak concentrations) and completely 
neglecting the TDM [130]. It was discovered from Study I (unpublished data) that 
at the Children’s Hospital in 44 children with BSI between 2006 and 2010 who 
were treated with vancomycin, 34% (15/44) of these patients’ vancomycin TDM 
was not conducted. The duration of vancomycin therapy in these patients was 
more than 3 days. At the Children’s Hospital, vancomycin TDM is recommended 
at minimum on the third and fifth days during therapy and after that if the therapy 
is longer than one week. 
Regarding the prevalence of inappropriate AMT, the results of Study I 
(prevalence of 17%) were in line with other studies. The percentage of patients 
receiving inappropriate AMT varied (20–24%) in empirical AMT [59, 60, 61] and 
in targeted AMT (16–37%) [63–65]. Zaragoza et al. showed that inappropriate AMT 
was not associated with increased mortality [60]. This finding is in accordance with 
Study I where the inappropriate AMT was not associated with increased mortality. 
A plausible reason for this is that the infections in the Children’s Hospital were 
rarely fatal due to the low virulence of the causative pathogens. Hence, most of 
the patients receiving inappropriate AMT suffered from infections caused by 
CONS. However, resistance towards antimicrobials is constantly increasing and 
the virulence of pathogens is expected to grow [35]. In addition, multiple studies 
show that inappropriate AMT is associated with increased mortality [58, 59, 63–65]. 
It is important that these factors be considered at the Children’s Hospital when 
implementing an ASP.
Currently the Children’s Hospital does not have an official ASP. Study I 
highlighted the importance of audits investigating the quality of AMT for different 
patient groups (neonates vs. older children) and different indications. Regular audits 
regarding clinical quality, safety and efficacy of prescribed and implemented AMT 
are being recommended by many studies as key components of ASPs [83–91]. As 
well, lack of TDM when using vancomycin was discovered. Utilizing ASP guidance 
on vancomycin therapy and monitoring at paediatric hospitals has been proven to 
decrease excessive vancomycin use and increase appropriate TDM [125]. Education 
81
of healthcare professionals is of high importance as well in achieving prudent use 
of antimicrobials [83–91]. Study I demonstrated that medical doctors need to 
be further educated regarding appropriate prescribing of antimicrobials. There 
are numerous ASPs utilized in children’s hospitals that can be further applied 
and developed for the Children’s Hospital by a team of medical doctors, clinical 
microbiologists, nurses and clinical pharmacists [92, 133, 134]. According to the 
Infectious Disease Society of America and the Society for Healthcare Epidemiology of 
America, a modern and functional ASP should include infectious diseases physicians, 
clinical pharmacists with infectious diseases training, a clinical microbiologist and 
a hospital epidemiologist [135].
6.2.  CONSUMPTION OF ANTIMICROBIALS (II) 
A study of 32 European paediatric hospitals reported that the most commonly used 
antimicrobials were ceftriaxone, ampicillin, cefuroxime and oral amoxicillin [104]. 
The profile of antibiotic use in the Children’s Hospital was very similar: beta-lactams 
were the most frequently used antibacterials.
From 2003 to 2013, there was a clear local rise in the consumption of penicillins 
and three major changes in the use of penicillins could be seen. The reduction in 
the use of ampicillin was obviously due to the change in guidelines on neonatal 
infections: penicillin G replaced ampicillin. This change was introduced because of 
the very low frequency of listeria infections. Recommendation of empiric therapy 
of early neonatal sepsis was changed from ampicillin (+ an aminoglycoside) to 
penicillin G (+ an aminoglycoside). Later on, a clear reduction in the consumption 
of penicillin G was noticed in 2011–2012. The reduced consumption of penicillin G 
took place at the same time as the pneumococcal conjugate vaccine was introduced 
to the national immunization program in 2010. A reduction of approximately 80% 
in the numbers of invasive pneumococcal infections was seen from 2011 to 2013 
when compared to the pre-immunization era (data not shown). 
A third significant change was seen in the use of piperacillin-tazobactam (PIP-
TAZ) in 2012. This increase was due to new recommendations in the empiric 
treatment of sepsis in neutropenic patients. PIP-TAZ monotherapy replaced the 
previously used combination of ceftazime+cloxacillin in the treatment of patients 
with neutropenia and sepsis.
The increased use of carbapenems was the most prominent finding of Study 
II. This change has been reported by other European countries and hospitals in 
both adults and children [104, 117]. One reason for this has been that oncologists 
have become more concerned about infections caused by Pseudomonas and other 
multiresistant gram negative bacteria. Hence, guidelines were updated, and previous 
empiric therapy with a combination of cephalosporins and aminoglycosides was 
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replaced by either carbapenems or piperacillin tazobactam. The same practice has 
taken place in other Scandinavian countries [136]. On the other hand, the use of 
other anti-Pseudomonas drugs (aminoglycosides, ceftatzidime, fluoroquinolones) 
did not increase significantly from 2003 to 2013.
The increased use of carbapenems should, however, be carefully evaluated. 
The overuse may induce an increase in numbers of carbapenem-resistant bacteria 
[137]. Other disadvantages associated with the use of the carbapenems may be an 
increased number of fungal infections. In addition, carbapenems are active against 
several anaerobic bacteria of the gut, which may cause disturbances of the normal 
flora resulting in alterations in the microbiome. 
The use of vancomycin decreased from 2003 to 2013. One reason for this might 
be the extensive training given to prescribers on the appropriate use of vancomycin 
[138]. Empiric misuse of vancomycin in staphylococcal infections is relatively 
common, despite the fact that MRSA infections were very rare at the Children’s 
Hospital. MRSE infections, on the other hand, were relatively frequent, but these 
infections rarely require vancomycin initially. Another reason for the decline in 
the consumption of vancomycin may be the increased consumption of teicoplanin. 
The consumption of vancomycin and teicoplanin in DDDs cannot, however, be 
compared by using DDDs. Teicoplanin was more often prescribed for older children 
with malignancies, whereas vancomycin was more frequently given to patients in 
neonatal units.
The overall consumption of antifungals decreased somewhat during the study 
period. Novel antifungals were rapidly adapted into clinical use despite lack of data on 
their safety and efficacy [139]. The most frequently used antifungal was fluconazole, 
followed by caspofungin and amphotericin B (mostly liposomal). However, the 
use of both amphotericin B and fluconazole decreased over the years and these 
antifungals were replaced by novel azoles (voriconazole and posaconazole) and 
echinocandins (caspofungin and micafungin). These drugs are costly compared to 
azoles and amphotericin; however, data suggest that they may be safer for children 
than conventional therapies for candidaemia [139–143]. When further developing 
prudent use of antimicrobials at the Children’s Hospital, the cost-benefit analysis 
of new expensive therapies can be likewise implemented to an ASP.
Regarding the use of antivirals, the total consumption of valganciclovir was the 
greatest, followed by sidofovir and tsanamavir. The use of aciclovir, valaciclovir 
and valganciclovir has increased, whereas the use of ganciclovir has decreased. In 
Europe, the use of antivirals has varied greatly mainly because of the use of HIV/
AIDS drugs [144]. In Finland, the prevalence of HIV is very low and therefore 
consumption of anti-HIV medications is minimal [145]. 
Defined daily doses were used for measuring antimicrobial consumption in 
children. Although the DDDs are definitely not ideal for measuring consumption 
of antimicrobials in children, Study II was able to describe how the consumption of 
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different antimicrobials has changed from 2003 to 2013 in this tertiary children’s 
hospital. Thus, despite the shortcomings of this method, it allows us to compare 
temporal trends in a single hospital. DDDs are used in other children’s hospitals as 
well when investigating the consumption of drugs [146–149]. Similarly, a study by 
Wu et al. demonstrated that monitoring consumption of antimicrobials by using 
DDDs reduces their unnecessary use and resistance [150]. Hence, a culture-guided 
de-escalation of antimicrobials is an effective element of an ASP. The strength 
of Study II was the large amount of material covering the consumption of all 
antimicrobials used in the Children’s Hospital during a period of 11 years. This 
long surveillance period gives good insight into the consumption of antimicrobials 
in a tertiary care hospital in a country with a relatively low number of multiresistant 
bacteria such as MRSA and ESBL. 
Study II cannot be directly compared to other hospitals with different patient 
profiles. Similarly, the consumption of these pharmaceuticals cannot necessarily be 
compared to countries where multiresistant bacteria are more frequent. Likewise, 
guidelines for antimicrobial use can differ from country to country. In addition, 
the choice and dosing of an antimicrobial for a certain infection can vary. As well, 
in children, the quantification of consumption by using DDDs is not as precise as 
that of adults. Therefore, the consumption of different antimicrobials cannot be 
directly compared since the DDDs vary greatly between different drugs. Also, if the 
use of one antimicrobial is reduced in the neonatal ward, it will most likely not be 
seen in DDD figures since the dose of antimicrobial for neonate is so much smaller 
compared to one DDD, which is the recommended daily consumption for an adult 
[151,152]. Hence, if the same use of the drug is reduced in a ward that takes care of 
primarily adolescent patients, it will be seen in decreased DDDs. 
Finally, to further estimate the consumption and rational use of antimicrobials, 
more data, such as prescription data, indications and the ages of the children, are 
needed to evaluate the trends in the use of different antimicrobials. Benchmarking 
to other hospitals nationally regarding antimicrobial consumption and policy is not 
as informative as comparing the Children’s Hospital with other tertiary paediatric 
hospitals in Nordic countries with similar patient profiles would be. In general, the 
AMT given at Helsinki’s Children’s Hospital is more complex compared to other 
paediatric hospitals in Finland. The Children’s Hospital, HUCH, is the only hospital 
with paediatric patients with complex oncology and stem cell transplantations, organ 
transplant, open heart surgery and other demanding surgeries. Seeking appropriate 
AMT policies can be done by comparing the Children’s Hospital to other Nordic 
countries and by utilizing tools and information provided, for example, by GARPEC 
(Global Antimicrobial Resistance, Prescribing, and Efficacy among Neonates and 
Children) [153]. The GARPEC project is a global surveillance network focused 
on collection of data on neonatal and paediatric antimicrobial prescribing and 
resistance.
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6.3.  OFF-LABEL USE OF ANTIMICROBIALS (III) 
Study III consisted of three separate studies investigating OL use in children 
(Table 9.). The main finding of Study III was that one-fifth of premature neonates 
weighing 400–2000g with blood culture positive infections received at least one 
antimicrobial OL (51/282). Study III shows a correlation between weight and the 
use of OL antimicrobials. An increase in birth weight was found to statistically 
significantly decrease the probability of OL usage.
In the second study, included in Study III, of 282 premature neonates, 16% were 
given meropenem. Despite the OL status of meropenem, it has been found to be 
safe and effective in infants [155]. In addition, many studies have been published on 
appropriate dosing regimens of meropenem in neonates [154–158]. At present, there 
is an ongoing process (NEOMERO research) to provide data for the authorisation 
of meropenem in neonates [159]. Meropenem is widely used in NICUs, and clinical 
experience suggests that it is safe to use in neonates. Lack of market authorisation 
may be due to the absence of a pharmaceutical company or research group to 
analyse available data and compile recommendations. 
In the second study of Study II, 3% of premature neonates were given rifampicin 
despite its OL status. Rifampicin has been on the market for decades, but very 
few studies on the use of rifampicin in combination with other antimicrobials in 
premature neonates [160–162] have been published. Taken together, the present 
data on rifampicin pharmacokinetics in neonates are insufficient [163], and it is 
unlikely that its OL status will change in the near future.
A few premature neonates in Study III were given parenteral ciprofloxacin OL. 
Ciprofloxacin has been shown to be a rare cause of adverse musculoskeletal effects 
in children [164]. The safety of ciprofloxacin has been studied with favourable results 
in full-term and premature neonates [165–166]. The follow-up periods of the treated 
patients for safety have, however, been relatively short—only one or two years. 
Among the 282 premature neonates, one was treated with caspofungin. For 
decades, amphotericin B and fluconazole have been the first-line antifungal therapies 
in severe fungal infections, having only recently been replaced by novel antifungals. 
Compared with amphotericin B, caspofungin seems to cause less adverse reactions 
in neonates with candidaemia [169], and it seems to be well tolerated and effective 
in premature and full-term neonates and older children [170–173]. 
As the examples discussed above indicate, OL status does not necessarily mean 
that the drug is not safe and effective to use in neonates or children. Research data 
related to dose, efficacy and safety may be available but have not been submitted to 
regulatory authorities for labelling. Age-appropriate dosing recommendations for 
children may be found for some commonly used drugs not labelled for children in 
formularies like BNFC (British National Formulary for Children), and databases such 
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as MicromedexR (US). These recommendations are given by clinical professionals 
and the recommendations are based on academic research and clinical experience. 
However, there are often no clear and exact recommendations for the youngest age 
group, like the premature neonates. Many antimicrobials used OL have established 
their place in the management of infectious diseases in neonates. Despite recent 
positive development in paediatric research, efforts are still needed, particularly 
regarding data on dosing and pharmacokinetics [2].
In addition to new drugs, many antimicrobials that have been on the market for 
decades are not labelled for children of all ages and particularly not for neonates. In 
the Children’s Hospital’s NICU during the study period, 35% of the most frequently 
used antibacterials were used OL. The risks of OL use in neonates clearly outnumber 
the risks for older children [9, 10, 174]. Neonates, particularly premature, may be 
more prone to adverse effects of drugs due to their undeveloped organ systems. 
Systematic literature review on drug use in NICUs conducted by Krzyżaniak et al. 
concluded that safety concerns regarding drug use in neonates include high use of 
antibiotics and OL and unlicensed medicines. Likewise, especially for neonates, it is 
not only the lack of data concerning the active drug, but also that of the excipients 
that need to be gathered for safety and efficacy [176]. Quality, safety and efficacy 
of AMT are also essential elements of ASPs. Hence, investigating and auditing of 
OL drug use should be included in a paediatric hospital’s ASP. 
6.4.  ANTIMICROBIAL MEDICATION ERRORS (IV) 
More than half of the errors in Study IV occurred with beta-lactams (84/157, 54%), 
which are the most consumed antimicrobials at the Children’s Hospital. This study 
demonstrates that many antimicrobial errors occur due to the large consumption 
of these drugs in use at the Children’s Hospital [123]. The results suggest that, in 
general, there are no drug-specific errors and the safety of AMT can be presumed 
to be of good quality.
In this study, the drugs with the most commonly reported errors were related 
to use of cefuroxime (15/157, 10%), penicillin G (15/157, 10%), vancomycin (13/157, 
8%), netilmicin (12/157, 8%) and amoxicillin (12/157, 8%). Fluconazole was the 
most commonly reported antifungal involved in all antimicrobial errors (5/157, 
7%). This finding was not surprising since these drugs are also the most frequently 
used drugs in the Children’s Hospital [123]. These results are mostly in line with 
literature. Antibiotics commonly involved in medication errors in neonates have 
been amikacin [177], benzylpenicillin [178], gentamicin [177–179], vancomycin [177, 
178] and piperacillin tazobactam [178], whereas in older children the medications 
are penicillin G [180] and gentamicin [180].
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Most of the errors occurred with parenteral administered antimicrobials. The 
most common error types for intravenous administration were wrong dose/dosing 
interval, preparation of the drug prior to administration and omission (Table 16.). 
The most common error types for orally administered antimicrobials were omission, 
wrong dose/dosing interval and prescription. It is notable that omission errors occur 
often with both intravenously and orally administered drugs. Omission error was 
the most common error type regarding parenteral administration in GEN and INF 
wards and regarding oral administration in GEN, HEM-ONC and INF wards. Based 
on Study IV, an omission error was a typical error occurring with antimicrobials. 
The data show that 25% (37/149) of all errors were omission errors, whereas in 
other studies, not focused only on antibiotics, the prevalence of omission errors 
was lower at 12–23% [23, 26, 33]. This is an interesting finding and suggests that 
omission errors occur more often with antimicrobials. Compared to many other 
drugs in use at hospitals, most antibiotics are administered several times a day, 
which may increase the risk of staff forgetting to administer them. 
Medication errors are common among cephalosporins because the generic 
names of these drugs are very similar to each other (such as ceftazidime, ceftriaxone 
and cefuroxime). Hence, these drugs are well-known look-alike and sound-alike 
(LASA) medicines [181]. In Study IV, 5 patients (5/149, 4%) received a cephalosporin 
different from that which was prescribed. This may be due to the similar names of 
the drugs and also because the drugs are stored close to each other. Usually no major 
clinical harm took place after these errors. The antibiotic spectrum of these drugs 
is different, however, and using, for example, cefuroxime instead of ceftazidime in 
treating an infection caused by Pseudomonas species may be harmful. Hence, if 
medicine cabinets are organized by the active substance in alphabetical order, all 
cephalosporins are located next to each other. On the other hand, using generic 
names of the drugs clearly increases safety when compared with trade names. 
According to the Institute for Safe Medication Practices (ISMP), TallMan letters 
can be used in order to separate different cephalosporins from each other [182]. 
On the other hand, a large-scale study conducted in 42 US hospitals revealed that 
the use of TallMan letters did not prevent LASA medication errors [183]. 
In Study IV, 24% of errors were dose-related (36/149). A total of 3% (4/149) 
of patients received a double dose of oral amoxicillin (Table 17.). However, the 
consequence of such an error is not serious. The most likely consequence for 
the patient receiving too high a dose of antibiotic is loose stools and diarrhoea. 
Sometimes too high a dose may be more harmful. For example, a study investigating 
overdose of drugs that require renal dose adjustments discovered that of the 20 
most commonly overdosed drugs, 65% were antimicrobials (13/20) and one of 
those drugs was amoxicillin [184].
In Study IV, only two patients experienced clinically serious antimicrobial errors 
(2/149, 1%), i.e., overdosing of vancomycin and teicoplanin. Antimicrobial errors 
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are, fortunately, not often clinically significant as can be seen in this study. The 
findings are in accordance with other studies investigating medication errors in 
children, which found that clinically significant errors are rare [24, 25, 30]. 
In general, antimicrobials do not result in clinically significant adverse effects 
such as other drugs like opioids or cytotoxics. However, some errors, such as the 
ten-fold errors, are potentially dangerous to children and especially to neonates. 
Ten-fold errors in dose are well-known errors in paediatrics [185]. Ten-fold errors 
may easily occur when drugs are prepared for children from drug products aimed 
at adults. Hence, prior to administration to children, the drugs often need dilution 
to prepare a suitable dose and administration route for paediatric patients. Ten-
fold errors were, however, not commonly recorded in Study IV. There was only 
one ten-fold error that reached the patient: a premature infant received a dose of 
vancomycin ten times too high. The outcome was favourable, and no irreversible 
side effects developed. 
Overall, neonates experience the same types of errors as older children. They are, 
however, more prone to errors due to more complex preparation and administration 
phases of the drugs [177, 186]. Likewise, the pharmacokinetics and dynamics of 
the drugs are often not well known in children, especially in neonates [186]. These 
issues expose neonates more often to administration and dosing errors. 
Human factors contribute to medication errors. The times of shift changes 
of nurses are potentially hazardous periods of time to forget to administer 
antimicrobials, leading to an omission error. The most frequently reported primary 
causes for omission errors were related to environment, equipment and resources 
(10/31, 32%). There were altogether 66 administration errors (63%, 66/105) 
reported from GEN, HEM-ONC and INF. Out of those, 18% of reports stated that 
there were no special circumstances contributing to the error and that the situation 
was normal when the error occurred (12/66, 18%). This finding highlights the 
fact that no matter what the circumstances are, errors do occur. This is why it is 
particularly important to develop protective measures that cover all circumstances. 
Several free comments were also given by the persons who reported errors. In these 
comments, the following root causes for errors in GEN, HEM-ONC and INF were 
given: being busy, different practices in different wards, often changing staff, not 
enough knowledge or education, too many patients/nurse and many patients with 
difficult co-morbidities. 
The number of error reports has increased over the years in the Children’s 
Hospital, and the use of the HaiPro tool is constantly increasing. This increase is 
most likely due to increased awareness of the HaiPro system and promotion of a 
blame-free atmosphere regarding errors occurring at the hospital. However, the 
reporting activity has not yet reached a plateau and errors remain under reported 
(Figure 14.).
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Medical doctors submitted only 3% of antimicrobial error reports. This is very 
concerning, and they should be actively educated about the benefits of the reporting 
system and their reporting should be also followed. Although medical doctors did not 
prepare and administer the drugs, they prescribed the drugs and if the prescription 
were inappropriate, e.g., an inappropriate dose, it could lead to a medication error 
that reaches the patient. The lesser activity of medical doctors might be explained 
by their role as prescribers. The consulting doctor may never hear about a patient 
after prescribing a drug unless a problem occurs with the therapy. Hence, the doctors 
may not be eager to report identified errors due to lack of understanding of the 
workflow leading to a medication error. Even though the prescription might be 
appropriate (e.g., correct drug, correct patient, correct dose, correct administration 
route), errors can occur. For example, if the prescription itself was not clear and 
accurate for the nurse administering the drug, an error can occur. Communication 
is challenging in all work environments, and special emphasis should be placed on 
communication when training staff. Currently, medical doctors receive feedback 
from obvious prescription errors, such as too high a dose of a drug or a wrong drug 
prescribed, but less obvious errors are perhaps not easily spotted by the healthcare 
staff.
Most of the reported errors reached the patient (84%). This indicates that 
healthcare professionals at the Children’s Hospital mainly report on errors that 
reached the patient. Reporting of near miss errors is also important because if 
only the errors reaching the patients are being reported, it will be increasingly 
challenging to prevent errors if there are not sufficient data regarding near miss 
cases. In Study IV, HEM-ONC reported more near miss errors than other wards. 
This might be due to more potent and toxic drugs in use in HEM-ONC compared to 
other wards. Hence, in general, the consequences in HEM-ONC may be more severe 
for the patient if medication error occurs. Healthcare workers see the importance 
of reporting near miss errors in HEM-ONC in order to create protective measures.
While there were only two clinically significant antimicrobial errors, these results 
suggest that the following issues should be addressed at the hospital in order to 
further improve safe and effective antimicrobial therapy and promote a culture of 
medication safety: encourage medical doctors’ activity in reporting errors, encourage 
all healthcare professionals to report near miss errors more often, provide nurses 
with sufficient time without distractions when preparing or administering drugs, 
unify practices between all wards (there should not be different practices between 
different wards inside the same hospital) and add more clinical pharmacists to the 
multidisciplinary team. Clinical pharmacists in wards decrease medication errors 
[177].
An ASP is valuable in reducing antimicrobial prescription errors, for example 
[187]. Manias et al. investigated which types of interventions helped to reduce 
medication errors in paediatric intensive care [188]. They discovered that the 
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following interventions reduced medication errors: computerized medical doctor 
order entry, intravenous systems, education modes, protocols and guidelines, clinical 
pharmacist involvement and support systems for clinical decision making. Few 
studies have investigated digital programs reducing medication errors, including 
electronic trigger detection tools that can detect overdoses of antibiotic [189] 
and electronic medication reconciliation at discharge stage [190]. These types of 
programs could also be useful at the Children’s Hospital. 
6.5.  STRENGTHS AND LIMITATIONS OF THE STUDIES I–IV
There were several limitations in Study I. First, Study I was retrospective and it was 
possible to collect only data that were recorded. Second, the number of patients 
in this study was relatively small and therefore general assumptions regarding the 
overall occurrence of true faults were difficult to calculate. Third, the antimicrobials 
used were evaluated by an expert panel. Thus, the classification (appropriate vs. 
inappropriate) was of course a subjective opinion of the panel. The evaluation was, 
however, based on microbiological in vitro data. Fourth, the pathogens isolated 
from the blood cultures may not always represent the sole pathogen that causes 
the infection. Hence, sometimes the care-provider may be reluctant to de-escalate 
the chosen antibacterial therapy when the blood culture shows growth of a single 
pathogen. This may result in treating children with severe underlying conditions 
with broad-spectrum drugs (“just in case”). 
Regarding Study II, the DDDs are not an ideal measurement of drug use in 
children. DDD is the assumed average maintenance dose per day for a drug used 
for its main indication in adults [95, 96]. However, as long as paediatric DDDs 
are lacking, DDDs may be used to describe paediatric consumption of individual 
antimicrobials over a certain period of time in a setting where no major changes 
in the hospital patient population takes place. A novel, more accurate method of 
evaluating paediatric drug use is, however, urgently needed. 
There are several limitations in Study III. Since the data were collected from a 
single hospital, the sample size was relatively small. However, the main finding of 
Study III regarding the relatively frequent use of OL antimicrobials, especially among 
neonates, is universal and concerns most NICUs. The retrospective nature of the 
study created difficulties in data collection. The results of Study III underestimate the 
true OL use of antimicrobials in neonates, as in order to comprehensively evaluate 
the prevalence of off-label use, dose and indication should be identified in addition 
to the age of the patient. In Study III, the data regarding the doses and dosing of 
antimicrobials for premature infants could not be collected because the electronic 
records mainly did not enable this. 
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6. Discussion
Data from Study IV were from a single institution, and results cannot be 
generalized to other environments. However, many common aspects were 
discovered with the existing literature. In Study IV, the number of medication 
errors included was relatively small; however, the data were collected throughout 
the period available for electronic medication errors. 
6.6.  RECOMMENDATIONS AND CLINICAL IMPACT OF STUDIES 
I–IV
The use of antimicrobials in children was evaluated in four studies. The results 
from the Studies I–IV are summarized and follow-up at the Children’s Hospital 
shown in Table 18. So far, education of healthcare staff has been a main measure 
supporting the rational use of antimicrobials. This thesis has also triggered a few 
studies regarding appropriate use of AMT at the Children’s Hospital.
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6.7.  ANTIMICROBIAL THERAPY IN THE CHILDREN’S HOSPITAL 
AND RECOMMENDATIONS FOR ANTIMICROBIAL 
STEWARDSHIP PROGRAM
There are five tertiary university paediatric hospitals in Finland. The Children’s 
Hospital, HUCH, is the only hospital with paediatric patients with complex oncology 
therapies and stem cell transplantations, organ transplant, open heart surgery 
and other demanding surgeries. Hence, the antimicrobial therapy in Helsinki’s 
Children’s Hospital is more complex compared to other paediatric hospitals in 
Finland. Comparing the five children’s hospitals is relatively difficult since there is 
significant diversity among them. 
At the moment, there is no official ASP at the Children’s Hospital. Use of 
antimicrobials is controlled and monitored in passive ways such as education of 
staff, follow-up on consumption of antimicrobials and resistance rates at the hospital. 
At the Children’s Hospital, the HUS-pharmacy delivers data on consumption of 
antimicrobials twice a year to the infectious diseases consultants. These data include 
drug consumption according to medical ward. Currently, there are four infectious 
diseases consultants working at the hospital. 
Even though the Children’s Hospital is a relatively small hospital, more active 
measures are recommended in order to ensure more prudent use of antimicrobials. 
Currently, there is ongoing research regarding antimicrobial prophylaxis prior to 
surgery. The duration of AMT, such as prophylaxis for surgery or AMT for infection, 
is important to monitor. The duration of AMT should be more investigated. Auditing 
the quality, safety and efficacy of AMT conducted in individual patients is of high 
importance as well. Currently the indications of prescribed antimicrobials are 
audited four times a year. Regarding antimicrobial resistance, a few broad-spectrum 
antimicrobials could have limited prescription rights and in these cases, a general 
practitioner should always consult an infectious diseases specialist. 
Currently, electronic systems for patient data are under development in Finland. 
Epic (in Finland called Apotti), an extensive change project of the social services 
and healthcare field, will unify digital patient data between hospitals operating in 
the Finland area (HUS area) [191]. In the Children’s Hospital, measures of building 
a trigger tool for medical doctors prescribing antimicrobials is under consideration 
related to Apotti. When prescribing antimicrobials, there could be an obligatory 
“questionnaire” for every antimicrobial course prescribed. The prescriber would 
document if the AMT is empirical or targeted, what the indication is and the 
expected duration of therapy in days. These kinds of useful electronic tools are also 
introduced by two studies [189, 190]. Overall, enhanced real-time communication 
among different healthcare professionals such as prescribers, nurses, clinical 
microbiologists and clinical pharmacists could be supported via Apotti.
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Systematic review by Schuts et al. offers an evidence-based list of key measures 
assuring the prudent use of antimicrobials. This list includes five core elements: 
1) empirical treatment according to local or national guidelines, 2) de-escalation 
of treatment, 3) parenteral-to-oral switch, 4) therapeutic drug monitoring and 
5) restricted antimicrobial lists [90]. The current use of these measures and 
proposed new measures at the Children’s Hospital can be seen in Table 19. These 
five core elements have an effect on clinical outcome, adverse events, treatment 
costs and antibiotic resistance rates. Regarding parenteral to oral switch, clinical 
pharmacists have knowledge on switching highly bioavailable antimicrobials from 
the intravenous route to the oral route for patients who are good candidates [192]. 
These antimicrobials include, for example, quinolones, metronidazole, macrolides, 
doxycycline, clindamycin, rifampicin, linezolid and fluconazole. The efficacy of oral 
administration of these antimicrobials is almost equivalent to the efficacy of the 
intravenous route. 
Recommendations regarding prudent use of antimicrobials, research and ASP 
at the Children’s Hospital are introduced in Table 20. Establishing a coordinated 
and systematic ASP for the Children’s Hospital is supported by many studies 
conducted in paediatric hospitals [125, 187, 193–196]. Annual audits of antimicrobial 
consumption and evaluation of the appropriateness of AMT for different indications 
and patient groups should be conducted regularly. Moreover, involving a clinical 
pharmacist (specialized in infectious diseases) on the ASP team would be beneficial 
according to many studies [197–200]. Pharmacists trained in infectious diseases can 
also coordinate an ASP and conduct interventions and audits independently [201]. 
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Table 20. Recommendations for the Children’s Hospital based on this thesis.
Practical recommendations
•	 Establishing a coordinated and systematic ASP for the Children’s Hospital
•	 Establishing a new position for infectious diseases pharmacist for HUS area – the infectious 
diseases pharmacist can be consulted by the Children’s Hospital as well
•	 Creating new electronic tools for assuring the prudent use of antimicrobials by offering 
guidance on appropriate prescribing and trigger tools related to prescribing, monitoring of 
prescribed antimicrobials and enabling trigger tools for identifying risk factors of AMT in 
children
Research recommendations
•	 Establishing a research group consisting of medical doctors, nurses, clinical microbiologists 
and clinical pharmacists to conduct benchmarking from other Nordic tertiary paediatric 
hospitals and implementation of an ASP particularly designed for Children’s Hospital
•	 Research and audits regarding the quality, safety and efficacy of AMT with different 
paediatric patient groups and indications
•	 Retrospective audits regarding TDM taken with antimicrobials requiring TDM 
•	 Research regarding restricted antimicrobials in Nordic countries and, if required, 
implementation of “restricted antimicrobials” list 
•	 Research regarding the current practices on parenteral to oral switch with AMT
•	 Investigation on how the co-operation of HUS-pharmacy and Children’s Hospital could be 
further supported and enforced regarding implementation of ASP to the Children’s Hospital
ASP=antimicrobial stewardship program, AMT=antimicrobial therapy, TDM=therapeutic drug 
monitoring, HUS=Hospital District of Helsinki and Uusimaa
6.8.  FUTURE CONSIDERATIONS
Based on Studies I–IV, there are numerous suggestions for further studies. First, 
the quality of AMT in BSIs is an area lacking in information on children. Therefore, 
related to Study I, it is reasonable to recommend research and audits for other 
paediatric hospitals treating BSI patients and patients with other hospital infections 
such as (other) post-surgery infections. Severe or fatal harm may result for the 
patients whose hospital infections are undertreated, i.e., blood culture results 
should be acted upon accordingly at all times. If, after approximately 48 hours 
from the diagnosis of BSI, the decision regarding appropriate targeted AMT is 
not re-evaluated against the empirical AMT, this is alarming. In some hospitals 
abroad, such as in the UK and US, clinical pharmacists are conducting regular 
audits regarding appropriate use of antimicrobials [199, 202]. Pharmacists are able 
compare the conducted AMT to local guidance or national policies. A retrospective 
study regarding the impact of evaluation on AMT conducted by clinical pharmacists 
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should be performed in Finland. This study would investigate the possible role of 
pharmacists in these types of tasks. This study would aid the co-operation between 
different healthcare professionals and strengthen co-operation between infectious 
disease consultants and clinical pharmacists working in medical wards or at hospital 
pharmacies.
Second, all factors that compromise paediatric AMT safety should be targeted 
for further research, including OL use of antimicrobials, especially in premature 
neonates, and antimicrobial medication errors. In Study III, it was discovered that OL 
use of antimicrobials is common in neonates. Further studies should be conducted 
about the correct dosing of these drugs to this vulnerable patient group. Doses from 
adults cannot always be extrapolated for neonates according to weight or other 
parameters. In addition, children are prone to different kinds of medication errors 
compared to adults. A typical example is ten-fold errors regarding dosing. Hence, 
it would be important to further investigate antimicrobial errors in paediatrics. 
These errors are not likely to cause significant risk for the patient, but due to the 
large volume of these drugs in use, it is important to invest in safe AMT. Study IV 
demonstrated that two clinically significant errors occurred with antimicrobials, both 
with renal toxic antimicrobials (vancomycin and teicoplanin). Hence, these groups 
of antimicrobials with the potency to cause severe harm if used inappropriately, 
should be specifically targeted in future studies. Also, it was discovered that when 
preparing drugs for children from products aimed at adults, the process can cause 
significant risks possibly leading to medication errors. Therefore, the preparation 
phase of antimicrobials, such as a nurse or pharmacist diluting a drug for a child 
before administering it, should be targeted for research in order to create safety 
warnings for healthcare workers preparing antimicrobials for administration at 
hospitals or at other facilities. 
Third, antimicrobial resistance is a future global threat. It is important to perform 
regular surveillance on the antimicrobials used in hospitals in order to gather 
information nationally and globally to further evaluate the situation and create 
accurate local protocols to reserve broad-spectrum antimicrobials for cases where 
they are the only drugs working against resistant pathogens. For example, in Study 
II, an alarming increase was discovered in the use of carbapenems in the Children’s 
Hospital. It would be valuable to investigate the situation in other children’s hospitals 
in Finland and create a national surveillance method for antimicrobial consumption 
in children. 
Future research regarding prudent use of antimicrobials in the Children’s Hospital 
and establishing a coordinated and systematic ASP to the Children’s Hospital is 
introduced in Table 20. The cost-effectiveness of different types of measures relating 
to ASP should be researched and evaluated prior to implementation. 
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7. CONCLUSIONS
The conclusions of Studies I–IV are the following:
1. Surprisingly, many patients received inappropriate AMT for BSI. Despite the 
relatively high number of inappropriate AMT given, only three cases were directly 
harmful to the patient who did not receive effective AMT for BSI. However, 
suboptimal therapy of, for example, staphylococcal infections was not uncommon. 
No patient died due to this, and overall the mortality was low compared to 
international studies with paediatric BSI patients.
2. Increased use of carbapenems during 11 years of surveillance was the most 
significant finding. This finding is in line with other European hospitals and 
should be evaluated carefully since the selective pressure caused by these drugs is 
a potential threat. The year-over-year consumption of antibacterials was in general 
relatively stable and new antibacterials were put into use conservatively. In contrast 
to antibacterials, novel antifungals were rapidly adopted into use despite scarce 
evidence of their safety in children. 
3. Off-label use of antimicrobials according to age was surprisingly low in the 
point prevalence study in children 0–17 years old. The prevalence of such use is 
more prominent in preterm and full-term neonates and is more likely the lower 
the neonate’s birth weight is at the time of antimicrobial therapy. More studies in 
neonates, particularly regarding dosing and pharmacokinetics of antimicrobials, 
are urgently needed.
4. Reports from antimicrobial medications given in the inpatient services over 5 
years have shown a minimal predilection for specific groups being high risk. No 
significant antimicrobial medication errors reported via HaiPro regarding specific 
antimicrobials were found. Both system-based high reliability safeguards as well as 
human factors solutions will continue to be important. Medical doctors should be 
further educated and informed about the importance of reporting medication errors. 
More good quality studies, with large enough data, are needed in order to determine 
the most efficient interventions to prevent antimicrobial errors in paediatrics. 
The main conclusions from each of the Studies (I–IV) have been used to improve and 
develop current practices mainly by educating healthcare professionals regarding 
appropriate antimicrobial therapy and medication safety. The Children’s Hospital 
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does not currently have an official ASP; however, this thesis has initiated projects 
regarding prudent use of antimicrobials and further launch of an ASP. Establishing 
a coordinated and systematic ASP for the Children’s Hospital would be beneficial 
and supported by literature. The cost-effectiveness of different types of measures 
relating to ASP should be researched and evaluated prior to implementation. 
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